CUMULATIVE SUPPLEMENT 5

JAN'92-MAY'92

APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

12TH EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION

APPROVED DRUG PRODUCTS with THERAPEUTIC EQUIVALENCE EVALUATIONS

12TH EDITION

Cumulative Supplement 5

May 1992

CONTENTS

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

12TH EDITION

CUMULATIVE SUPPLEMENT 5

MAY 1992

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 12th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Division of Blood and Blood Products and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Division of Blood and Blood Products lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Additions new to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >ADD> to the left of the line on which new information exists. The >ADD> symbol is then dropped in subsequent Cumulative Supplements for that item. A newly approved product is also identified by a lozenge (◆) to the right of its strength which remains throughout all Cumulative Supplements for this edition.

Deletions new to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >DLT> (DELETE) to the left of the line containing overstruck print. The >DLT> symbol is dropped in subsequent Cumulative Supplements for that item. The overstruck print remains in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements for this edition. However, the overstruck print in the Patent and Exclusivity Data is dropped in subsequent Cumulative Supplements.

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the " ∂ " symbol to designate their non-marketed status. All products having a " ∂ " symbol in the 12th Cumulative Supplement of the 12th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 13th Edition.

1.2 CEFADROXIL/CEFADROXIL HEMIHYDRATE ACTIVE INGREDIENT HEADING

The active ingredient heading Cefadroxil/Cefadroxil Hemihydrate replaces the active ingredient heading Cefadroxil which is currently listed in the Approved Drug Products with Therapeutic Equivalence Evaluations, 12th Edition. All products which are listed under Cefadroxil (which is understood to be the monohydrate form) in the 12th Edition will now be listed along with the newly approved duplicate drug products under the new active ingredient, Cefadroxil/Cefadroxil Hemihydrate.

1.3 PRODUCTS REQUIRING REVISED LABELING FOR FULL APPROVAL

Drug products in this category (1) initially received approval only on the basis of safety before effectiveness studies were required, or (2) were conditionally approved under the temporary exemption that allowed these products to be marketed while effectiveness studies were being conducted. Listed below are those drugs which are now required to revise their labeling and provide additional information necessary for full approval on the basis of requirements listed in the Federal Register. As approval is granted by the Agency for a specific product, based on additional information submitted by the applicant, the product will be included in the appropriate Drug Product List.

Products	Federal Register Reference
Nitroglycerin (capsule, controlled release;oral)	SEP 7, 1984 (49 FR 35428)
Nitroglycerin (tablet, controlled release;oral)	SEP 7, 1984 (49 FR 35428)
Nitroglycerin (tablet, controlled release;buccal)	JUL 5, 1985 (50 FR 27688)
Tranylcypromine Sulfate	MAR 22, 1984 (49 FR 10708)

1.4 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant; or when an applicant changes its name; or when an applicant name is changed to meet internal publication standards. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial approved product lines are transferred between applicants, each approved product involved will appear as an applicant name change in the Cumulative Supplement.

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREIVATED NAME)
BARNES HIND PHARMACEUTICALS INC (BARNES HIND)	SOLA BARNES HIND (SOLA BARNES HIND)

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREIVATED NAME)
NORWICH EATON PHARMS INC SUB PROCTOR & GAMBLE CO (NORWICH EATON)	PROCTER & GAMBLE PHARMACEUTICALS INC (P&G)
RECKITT AND COLMAN PHARMACEUTICALS INC (R & C)	RECKITT AND COLMAN PHARMACEUTICALS INC (RECKITT AND COLMAN)

1.5 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1991) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 1991	MAR 1992	JUN 1992	SEP 1992
DRUG PRODUCTS LISTED	9584	9473		
SINGLE SOURCE	2187 (22.8%)	2222 (23.4%)		
MULTISOURCE	7397 (77.2%)	7251 (76.6%)		
THERAPEUTICALLY EQUIVALENT	6580 (68.7%)	6510 (68.7%)		
NOT THERAPEUTICALLY EQUIVALENT	664 (6.9%)	592 (6.3%)		
EXCEPTIONS[1]	153 (1.6%)	149 (1.6%)		
NEW MOLECULAR ENTITIES APPROVED	--	4		
NUMBER OF APPLICANTS	430	437		

[1]Amino acid-containing products of varying composition (see Introduction, page xvi of the List).

PRESCRIPTION DRUG PRODUCT LIST
12TH EDITION
CUMULATIVE SUPPLEMENT NUMBER 5 / JAN'92 - MAY'92

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

ACETAMINOPHEN AND CODEINE

AA	VITARINE	300MG;15MG	N87433 001
AA		300MG;30MG	N85917 001
AA		300MG;60MG	N87423 001

ACETAMINOPHEN AND CODEINE PHOSPHATE

∂	PARKE DAVIS	300MG;15MG	N85992 001
∂		300MG;30MG	N85218 002
∂	VITARINE	300MG;15MG	N87433 001
∂		300MG;30MG	N85917 001
∂		300MG;60MG	N87423 001

ACETAMINOPHEN W/ CODEINE PHOSPHATE

AA	CHELSEA	300MG;15MG	N87277 001 MAY 26, 1982
AA		300MG;30MG	N87276 001 MAY 26, 1982
AA		300MG;60MG	N87275 001 MAY 26, 1982
∂	CHELSEA	300MG;15MG	N87277 001 MAY 26, 1982
∂		300MG;30MG	N87276 001 MAY 26, 1982
∂		300MG;60MG	N87275 001 MAY 26, 1982
AA	PARKE/DAVIS	300MG;15MG	N85992 001
AA		300MG;30MG	N85218 002

ACETAMINOPHEN; HYDROCODONE BITARTRATE

ELIXIR; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	MIKART	500MG/15ML;5MG/15ML¤	N89557 001 APR 29, 1992

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	MIKART	500MG;5MG¤	N89697 001 JAN 28, 1992
> ADD >		650MG;10MG¤	N81223 001 MAY 29, 1992
B*	PHARM BASICS	500MG;5MG	N89291 001 MAY 29, 1987
∂	PHARM BASICS	500MG;5MG	N89291 001 MAY 29, 1987

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL

PROPOXYPHENE HCL AND ACETAMINOPHEN

AA	MYLAN	650MG;65MG	N83978 001
	∂	325MG;32MG	N83689 001
AA	MYLAN	650MG;65MG	N83978 001
		325MG;32MG	N83689 001

ACETOHEXAMIDE

TABLET; ORAL

ACETOHEXAMIDE

B*	PHARM BASICS	250MG	N70753 001 NOV 03, 1986
B*		500MG	N70754 001 NOV 03, 1986
∂	PHARM BASICS	250MG	N70753 001 NOV 03, 1986
∂		500MG	N70754 001 NOV 03, 1986

ACETYLCYSTEINE

SOLUTION; INHALATION, ORAL

ACETYLCYSTEINE

AN	CETUS BEN VENUE	10%¤	N72323 001 APR 30, 1992
AN		20%¤	N72324 001 APR 30, 1992

ALBUTEROL SULFATE

SOLUTION; INHALATION

ALBUTEROL SULFATE

AN	DEY	EQ 0.083% BASE¤	N72652 001 FEB 21, 1992

PROVENTIL

AN	SCHERING	EQ 0.083% BASE	N19243 002 JAN 14, 1987

VENTOLIN

AN	GLAXO	EQ 0.083% BASE¤	N19773 001 APR 23, 1992

SYRUP; ORAL

ALBUTEROL SULFATE

AA	LEMMON	EQ 2MG BASE/5ML¤	N73419 001 MAR 30, 1992

ALGLUCERASE

INJECTABLE; INJECTION
CEREDASE

> ADD >		GENZYME	10 UNITS/ML*	N20057 004
> ADD >				MAY 08, 1992

ALLOPURINOL

TABLET; ORAL
ALLOPURINOL

/AB/	/BOLAR/		/100MG/	/N18241/001/
				/NOV/16,/1984/
	∂ BOLAR		100MG	N18241 001
				NOV 16, 1984

AMIKACIN SULFATE

INJECTABLE; INJECTION
AMIKACIN

> ADD >				
> ADD >	AP	ELKINS SINN	EQ 50MG BASE/ML*	N63274 001
> ADD >				MAY 18, 1992
> ADD >	AP		EQ 250MG BASE/ML*	N63275 001
> ADD >				MAY 18, 1992

AMIKIN

> ADD >	AP	BRISTOL	EQ 50MG BASE/ML	N50495 001
> ADD >	AP		EQ 50MG BASE/ML	N62562 001
> ADD >				SEP 20, 1984
> ADD >	AP		EQ 250MG BASE/ML	N50495 002
> ADD >	AP		EQ 250MG BASE/ML	N62562 002
> ADD >				SEP 20, 1984

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL
/AMITRIL/

> DLT >				
> DLT >	/AB/	/WARNER/CHILCOTT/	/10MG/	/N83939/001/
> DLT >	/AB/		/25MG/	/N83937/001/
> DLT >	/AB/		/50MG/	/N83938/002/
> DLT >	/AB/		/75MG/	/N84957/001/
> DLT >	/AB/		/100MG/	/N85093/001/
> DLT >	/AB/		/150MG/	/N86295/001/
> ADD >		∂ WARNER CHILCOTT	10MG	N83939 001
> ADD >		∂	25MG	N83937 001
> ADD >		∂	50MG	N83938 002
> ADD >		∂	75MG	N84957 001
> ADD >		∂	100MG	N85093 001
> ADD >		∂	150MG	N86295 001

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL
AMITRIPTYLINE HCL

/BP/	/PAR/		/10MG/	/N88697/001/
				/SEP/25,/1984/
/BP/			/25MG/	/N88698/001/
				/SEP/25,/1984/
/BP/			/50MG/	/N88699/001/
				/SEP/25,/1984/
/BP/			/75MG/	/N88700/001/
				/SEP/25,/1984/
/BP/			/100MG/	/N88701/001/
				/SEP/25,/1984/
/BP/			/150MG/	/N88702/001/
				/SEP/25,/1984/
	∂ PAR		10MG	N88697 001
				SEP 25, 1984
	∂		25MG	N88698 001
				SEP 25, 1984
	∂		50MG	N88699 001
				SEP 25, 1984
	∂		75MG	N88700 001
				SEP 25, 1984
	∂		100MG	N88701 001
				SEP 25, 1984
	∂		150MG	N88702 001
				SEP 25, 1984

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HCL

/B*/	/PHARM/BASICS/		/EQ/12.5MG/BASE;5MG/	/N70477/001/
				/JAN/12,/1988/
/B*/			/EQ/25MG/BASE;10MG/	/N70478/001/
				/JAN/12,/1988/
	∂ PHARM BASICS		EQ 12.5MG BASE;5MG	N70477 001
				JAN 12, 1988
	∂		EQ 25MG BASE;10MG	N70478 001
				JAN 12, 1988

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL
PERPHENAZINE AND AMITRIPTYLINE HCL

/S/	/CHELSEA/		/50MG;4MG/	/N71558/001/
				/MAR/02,/1987/

AMOXICILLIN

CAPSULE; ORAL

POLYMOX

AB	BRISTOL MYERS	250MG¤	N63099 001 MAR 20, 1992
AB		500MG¤	N63099 002 MAR 20, 1992

UTIMOX

AB	PARKE/DAVIS	250MG	N62107 001
AB		500MG	N62107 002
	∂ PARKE DAVIS	250MG	N62107 001
	∂	500MG	N62107 002

POWDER FOR RECONSTITUTION; ORAL

AMOXICILLIN

AB	CLONMEL	125MG/5ML	N62927 001 NOV 25, 1988
AB		250MG/5ML	N62927 002 NOV 25, 1988
BX	CLONMEL	125MG/5ML	N62927 001 NOV 25, 1988
BX		250MG/5ML	N62927 002 NOV 25, 1988

UTIMOX

AB	PARKE/DAVIS	125MG/5ML	N62127 001
AB		250MG/5ML	N62127 002
	∂ PARKE DAVIS	125MG/5ML	N62127 001
	∂	250MG/5ML	N62127 002

AMPHOTERICIN B

INJECTABLE; INJECTION

AMPHOTERICIN B

AP	PHARMA TEK	50MG/VIAL¤	N63206 001 APR 29, 1992

AMPICILLIN SODIUM

INJECTABLE; INJECTION

POLYCILLIN-N

AP	BRISTOL	EQ 125MG BASE/VIAL	N50309 001
AP		EQ 250MG BASE/VIAL	N50309 002
AP		EQ 500MG BASE/VIAL	N50309 003
AP		EQ 1GM BASE/VIAL	N50309 004
AP		EQ 2GM BASE/VIAL	N50309 005
	∂ BRISTOL	EQ 125MG BASE/VIAL	N50309 001
	∂	EQ 250MG BASE/VIAL	N50309 002
	∂	EQ 500MG BASE/VIAL	N50309 003
	∂	EQ 1GM BASE/VIAL	N50309 004
	∂	EQ 2GM BASE/VIAL	N50309 005

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

AMCILL

AB	PARKE/DAVIS	EQ 250MG BASE	N62041 001
AB		EQ 500MG BASE	N62041 002
	∂ PARKE DAVIS	EQ 250MG BASE	N62041 001
	∂	EQ 500MG BASE	N62041 002

POLYCILLIN

AB	BRISTOL	EQ 250MG BASE	N50310 001
AB		EQ 500MG BASE	N50310 002
	∂ BRISTOL	EQ 250MG BASE	N50310 001
	∂	EQ 500MG BASE	N50310 002

POWDER FOR RECONSTITUTION; ORAL

AMCILL

AB	PARKE/DAVIS	EQ 125MG BASE/5ML	N62030 001
AB		EQ 250MG BASE/5ML	N62030 002
	∂ PARKE DAVIS	EQ 125MG BASE/5ML	N62030 001
	∂	EQ 250MG BASE/5ML	N62030 002

POLYCILLIN

AB	BRISTOL	EQ 100MG BASE/ML	N50308 004
AB		EQ 100MG BASE/ML	N61394 001
	∂ BRISTOL	EQ 100MG BASE/ML	N50308 004
		EQ 100MG BASE/ML	N61394 001

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID

POWDER FOR RECONSTITUTION; ORAL

POLYCILLIN-PRB

AB	∂ BRISTOL	EQ 3.5GM BASE/BOT; 1GM/BOT		N50457 001

ATENOLOL

TABLET; ORAL

ATENOLOL

AB	APOTHECON	50MG*		N73317 001 MAR 20, 1992
AB		100MG*		N73318 001 MAR 20, 1992
> ADD > AB	GENEVA	25MG*		N74052 001 MAY 01, 1992
> ADD > AB	LEDERLE	25MG*		N74099 001 APR 28, 1992
AB	MYLAN	50MG*		N73456 001 JAN 24, 1992
AB		100MG*		N73457 001 JAN 24, 1992

TENORMIN

AB	ICI	25MG		N18240 004 APR 09, 1990

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL

DIPHENOXYLATE HCL AND ATROPINE SULFATE

AA	∂ CHELSEA	0.025MG;2.5MG		N85876 001

DIPHENOXYLATE HCL W/ ATROPINE SULFATE

AA	∂ VITARINE	0.025MG;2.5MG		N86173 001

AZITHROMYCIN DIHYDRATE

CAPSULE; ORAL

ZITHROMAX

+	PFIZER	EQ 250MG BASE		N50670 001 NOV 01, 1991

BACLOFEN

TABLET; ORAL

BACLOFEN

AB	BIOCRAFT	10MG*		N73043 001 FEB 27, 1992
AB		20MG*		N73044 001 FEB 27, 1992
B*	∂ PHARM BASICS	10MG		N71260 001 MAY 06, 1988
B*	∂	20MG		N71261 001 MAY 06, 1988

> ADD > **BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE**

> ADD > TABLET; ORAL

> ADD > **LOTENSIN HCT**

> ADD > +	CIBA	20MG;25MG*		N20033 003 MAY 19, 1992
> ADD >		5MG;6.25MG*		N20033 001 MAY 19, 1992
> ADD >		10MG;12.5MG*		N20033 002 MAY 19, 1992
> ADD >		20MG;12.5MG*		N20033 004 MAY 19, 1992

BENZTROPINE MESYLATE

TABLET; ORAL

BENZTROPINE MESYLATE

AA	MUTUAL PHARM	1MG*		N81264 001 JAN 23, 1992
AA		2MG*		N81265 001 JAN 23, 1992

BENZTROPINE MESYLATE

TABLET; ORAL

BENZTROPINE MESYLATE

/B*/	/PHARM/BASICS/	/0.5MG/	/N89211/001/	/JUN/14,/1988/
/B*/		/1MG/	/N89212/001/	/JUN/14,/1988/
/B*/		/2MG/	/N89213/001/	/JUN/14,/1988/
	ə PHARM BASICS	0.5MG	N89211 001	JUN 14, 1988
	ə	1MG	N89212 001	JUN 14, 1988
	ə	2MG	N89213 001	JUN 14, 1988

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL

BETAMETHASONE DIPROPIONATE

AB	TARO	EQ 0.05% BASE¤	N73552 001 APR 30, 1992

BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDE

/AA/	/VITARINE/	/5MG/	/N84353/001/	
/AA/		/10MG/	/N84378/001/	
/AA/		/10MG/	/N84379/001/	
/AA/		/25MG/	/N84383/001/	
/AA/		/25MG/	/N84384/001/	
	ə VITARINE	5MG	N84353 001	
	ə	10MG	N84378 001	
	ə	10MG	N84379 001	
	ə	25MG	N84383 001	
	ə	25MG	N84384 001	

BITOLTEROL MESYLATE

SOLUTION; INHALATION

TORNALATE

/STERLING/WINTHROP/		/0.2%¤/	/N19548/001/	/FEB/19,/1992/
STERLING		0.2%¤	N19548 001	FEB 19, 1992

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

BRETYLIUM TOSYLATE

/AP/	/LYPHOMED/	/50MG/ML/	/N70134/001/	/FEB/12,/1986/
	ə LYPHOMED	50MG/ML	N70134 001	FEB 12, 1986

BUTABARBITAL SODIUM

TABLET; ORAL

/BUTABARBITAL SODIUM/

/AA/	/VITARINE/	/30MG/	/N85934/001/	
	ə VITARINE	30MG	N85934 001	

SODIUM BUTABARBITAL

/AA/	/WEST/WARD/	/15MG/	/N85418/001/	
/AA/		/30MG/	/N85432/001/	
	ə WEST WARD	15MG	N85418 001	
	ə	30MG	N85432 001	

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER

AP	MCGAW	33MG/100ML;5GM/100ML;30MG/100ML; 860MG/100ML¤	N20000 001 APR 17, 1992

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

RINGER'S IN PLASTIC CONTAINER

AP	MCGAW	33MG/100ML;30MG/100ML; 860MG/100ML¤	N20002 001 APR 17, 1992

CARBAMAZEPINE

TABLET; ORAL

CARBAMAZEPINE

>_DLT_>/AB/	/PARKE/DAVIS/	/200MG/	/N70429/001/	/JAN/02,/1987/	
>_DLT_> /B*/	/PHARM/BASICS/	/200MG/	/N70300/001/	/MAY/15,/1986/	
	ə PHARM BASICS	200MG	N70300 001	MAY 15, 1986	

CARBAMAZEPINE

TABLET; ORAL
CARBAMAZEPINE

>ADD>	∂ WARNER CHILCOTT	200MG		N70429 001 JAN 02, 1987
>ADD>				

CARISOPRODOL

TABLET; ORAL
CARISOPRODOL

/AA/	/VITARINE/	/350MG/	/N89566/001/ /AUG/30,/1988/
B*	VITARINE	350MG	N89566 001 AUG 30, 1988

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL
CEFADROXIL

AB	ZENITH	EQ 500MG BASE	N62766 001 MAR 03, 1987
/∂/		/EQ/500MG/BASE/	/N62766/001/ /MAR/03,/1987/

TABLET; ORAL
CEFADROXIL

AB	ZENITH	EQ 1GM BASE	N62774 001 APR 08, 1987
/∂/		/EQ/1GM/BASE/	/N62774/001/ /APR/08,/1987/

CEFTAZIDIME

INJECTABLE; INJECTION
/CEPTAZ/

	/GLAXO/	/500MG/VIAL/	/N50646/001/ /SEP/27,/1990/
		/1GM/VIAL/	/N50646/002/ /SEP/27,/1990/
		/2GM/VIAL/	/N50646/003/ /SEP/27,/1990/
		/10GM/VIAL/	/N50646/004/ /SEP/27,/1990/

CEFTAZIDIME (ARGININE FORMULATION)

INJECTABLE; INJECTION
CEPTAZ

AP	GLAXO	1GM/VIAL	N50646 002 SEP 27, 1990
AP		2GM/VIAL	N50646 003 SEP 27, 1990
AP		10GM/VIAL	N50646 004 SEP 27, 1990
		500MG/VIAL	N50646 001 SEP 27, 1990

PENTACEF

AP	SMITHKLINE BEECHAM	1GM/VIAL*	N64006 001 MAR 31, 1992
AP		2GM/VIAL*	N64006 002 MAR 31, 1992
AP		10GM/VIAL*	N64008 002 MAR 31, 1992
		6GM/VIAL*	N64008 001 MAR 31, 1992

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION
ROCEPHIN

	/ROCHE/	/EQ/250MG/BASE/VIAL/	/N62510/001/ /MAR/12,/1985/
	∂ ROCHE	EQ 250MG BASE/VIAL	N62510 001 MAR 12, 1985
		/EQ/500MG/BASE/VIAL/	/N62510/002/ /MAR/12,/1985/
	∂	EQ 500MG BASE/VIAL	N62510 002 MAR 12, 1985
		/EQ/1GM/BASE/VIAL/	/N62510/003/ /MAR/12,/1985/
	∂	EQ 1GM BASE/VIAL	N62510 003 MAR 12, 1985

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL
CHLORDIAZEPOXIDE HCL

/AB/	/PARKE/DAVIS/	/5MG/	/N85163/001/
/AB/		/10MG/	/N84598/001/
/AB/		/25MG/	/N85164/001/
	∂ PARKE DAVIS	5MG	N85163 001
	∂	10MG	N84598 001
	∂	25MG	N85164 001

CHLORDIAZEPOXIDE HYDROCHLORIDE

CHLORTHALIDONE

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

CHLORDIAZEPOXIDE HCL

/AB/	/WEST/WARD/	/5MG/	/N85014/001/
/AB/		/10MG/	/N85000/001/
/AB/		/25MG/	/N85294/001/
	∂ WEST WARD	5MG	N85014 001
	∂	10MG	N85000 001
	∂	25MG	N85294 001

CHLOROQUINE PHOSPHATE

TABLET; ORAL

CHLOROQUINE PHOSPHATE

/AA/	/WEST/WARD/	/EQ 150MG BASE/	/N83082/001/
	∂ WEST WARD	EQ 150MG BASE	N83082 001

CHLORPROPAMIDE

TABLET; ORAL

CHLORPROPAMIDE

/B*/	/PHARM/BASICS/	/100MG/	/N88708/001/ /AUG/30,/1984/
/B*/		/250MG/	/N88709/001/ /AUG/30,/1984/
	∂ PHARM BASICS	100MG	N88708 001 AUG 30, 1984
	∂	250MG	N88709 001 AUG 30, 1984
/AB/	/VITARINE/	/250MG/	/N84669/001/
	∂ VITARINE	250MG	N84669 001

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

>DLT< /AB/	/WARNER/CHILCOTT/	/25MG/	/N87515/001/ /JAN/24,/1983/
>DLT< /AB/		/50MG/	/N87516/001/ /FEB/09,/1983/
>ADD<	∂ WARNER CHILCOTT	25MG	N87515 001 JAN 24, 1983
>ADD<	∂	50MG	N87516 001 FEB 09, 1983

THALITONE

/AB/	/BOEHRINGER/INGELHEIM/	/25MG/	/N88051/001/ /NOV/12,/1982/
		/15MG/	/N19574/001/ /DEC/20,/1988/

CHLORTHALIDONE

TABLET; ORAL

THALITONE

BX	HORUS	25MG	N88051 001 NOV 12, 1982
		15MG	N19574 001 DEC 20, 1988

CHYMOTRYPSIN

POWDER FOR RECONSTITUTION; OPHTHALMIC

ALPHA CHYMAR

/AI/	/BARNES/HIND/	/750 UNITS/VIAL/	/N11837/001/
	∂ SOLA BARNES HIND	750 UNITS/VIAL	N11837 001

ZOLYSE

/AI/	/ALCON/	/750 UNITS/VIAL/	/N11903/001/
	ALCON	750 UNITS/VIAL	N11903 001

CINOXACIN

CAPSULE; ORAL

CINOBAC

AB	LILLY	250MG	N18067 001
AB	+	500MG	N18067 002

CINOXACIN

AB	BIOCRAFT	250MG‡	N73005 001 FEB 28, 1992
AB		500MG‡	N73006 001 FEB 28, 1992

CITRIC ACID; GLUCONOLACTONE; MAGNESIUM CARBONATE

SOLUTION; IRRIGATION

RENACIDIN

	/GUARDIAN/LABS/	/6.602GM/100ML;0.198GM/100ML;/ /3.177GM/100ML/	/N19481/001/ /OCT/02,/1990/
	GUARDIAN LABS	6.602GM/100ML;198MG/100ML; 3.177GM/100ML	N19481 001 OCT 02, 1990

CLEMASTINE FUMARATE

SYRUP; ORAL

CLEMASTINE FUMARATE

AA	COPLEY	EQ 0.5MG BASE/5ML‡	N73095 001 APR 21, 1992

CLEMASTINE FUMARATE

SYRUP; ORAL

TAVIST

AA DORSEY — EQ 0.5MG BASE/5ML — N18675 001 JUN 28, 1985

TABLET; ORAL

CLEMASTINE FUMARATE

AB LEMMON — 1.34MG¤ — N73282 001 JAN 31, 1992

AB — 2.68MG¤ — N73283 001 JAN 31, 1992

TAVIST

AB + DORSEY — 2.68MG — N17661 001

TAVIST-1

AB DORSEY — 1.34MG — N17661 002

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

CLINDAMYCIN PHOSPHATE

>ADD> AP GENSIA — EQ 150MG BASE/ML¤ — N63282 001 MAY 29, 1992 >ADD>

CLIOQUINOL; NYSTATIN

/OINTMENT;TOPICAL/

/NYSTAFORM/

/MILES/ — /10MG/GM;/ /100,000/UNITS/GM/ — /N50235/001/

∂ MILES — 10MG/GM; 100,000 UNITS/GM — N50235 001

CLOFIBRATE

CAPSULE; ORAL

CLOFIBRATE

AB PHARMACAPS — 500MG¤ — N73396 001 MAR 20, 1992

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL

CLORAZEPATE DIPOTASSIUM

/B*/ /PHARM/BASICS/ /3.75MG/ /N71242/001/ /MAY/20,/1987/

/B*/ /7.5MG/ /N71243/001/ /MAY/20,/1987/

/B*/ /15MG/ /N71244/001/ /MAY/20,/1987/

∂ PHARM BASICS — 3.75MG — N71242 001 MAY 20, 1987

∂ — 7.5MG — N71243 001 MAY 20, 1987

∂ — 15MG — N71244 001 MAY 20, 1987

CLOTRIMAZOLE

CREAM; TOPICAL

LOTRIMIN

/AT/ /SCHERING/ /1%/ /N17619/001/

BX + SCHERING — 1% — N17619 001

MYCELEX

/AT/ /MILES/ /1%/ /N18183/001/

BX MILES — 1% — N18183 001

COLCHICINE; PROBENECID

TABLET; ORAL

/PROBEN-C/

/BP/ /CHELSEA/ /0.5MG;500MG/ /N85552/001/

∂ CHELSEA — 0.5MG;500MG — N85552 001

CYANOCOBALAMIN

INJECTABLE; INJECTION

CYANOCOBALAMIN

/AP/ /LUITPOLD/ /0.03MG/ML/ /N80668/001/

∂ LUITPOLD — 0.03MG/ML — N80668 001

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CYCLOPENTOLATE HCL

/AT/ /BARNES/HIND/ /1%/ /N84863/001/

∂ SOLA BARNES HIND — 1% — N84863 001

SOLUTION/DROPS; OPHTHALMIC

CYCLOPENTOLATE HCL

/AT/ /BARNES/HIND/ /1%/ /N84863/001/

∂ SOLA BARNES HIND 1% N84863 001

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

DESIPRAMINE HCL

/B*/ /PHARM/BASICS/ /25MG/ /N71864/001/ /SEP/09/1987/

/B*/ /50MG/ /N71865/001/ /SEP/09/1987/

/B*/ /75MG/ /N71866/001/ /SEP/09/1987/

/B*/ /100MG/ /N71867/001/ /SEP/09/1987/

∂ PHARM BASICS 25MG N71864 001 SEP 09, 1987

∂ 50MG N71865 001 SEP 09, 1987

∂ 75MG N71866 001 SEP 09, 1987

∂ 100MG N71867 001 SEP 09, 1987

DESONIDE

LOTION; TOPICAL

DESOWEN

OWEN GALDERMA 0.05%¤ N72354 001 JAN 24, 1992

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

>ADD> POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
MCGAW 3.3GM/100ML;75MG/100ML; 300MG/100ML¤ N19630 049 MAY 07, 1992

>ADD> POTASSIUM CHLORIDE 0.11% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
MCGAW 3.3GM/100ML;110MG/100ML; 300MG/100ML¤ N19630 050 MAY 07, 1992

>ADD> POTASSIUM CHLORIDE 0.15% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
MCGAW 3.3GM/100ML;150MG/100ML; 300MG/100ML¤ N19630 051 MAY 07, 1992

>ADD> POTASSIUM CHLORIDE 0.22% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
MCGAW 3.3GM/100ML;220MG/100ML; 300MG/100ML¤ N19630 052 MAY 07, 1992

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

>ADD> POTASSIUM CHLORIDE 0.3% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
MCGAW 3.3GM/100ML;300MG/100ML; 300MG/100ML¤ N19630 053 MAY 07, 1992

DIAZEPAM

TABLET; ORAL

DIAZEPAM

>DLT>/AB/ /PARKE/DAVIS/ /2MG/ /N70209/001/ /SEP/04/1985/

>DLT>/AB/ /5MG/ /N70210/001/ /SEP/04/1985/

>DLT>/AB/ /10MG/ /N70222/001/ /SEP/04/1985/

>ADD> ∂ WARNER CHILCOTT 2MG N70209 001 SEP 04, 1985

>ADD> ∂ 5MG N70210 001 SEP 04, 1985

>ADD> ∂ 10MG N70222 001 SEP 04, 1985

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL

DIETHYLPROPION HCL

/AA/ /VITARINE/ /25MG/ /N85916/001/

∂ VITARINE 25MG N85916 001

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CARDIZEM CD

>ADD> BC + MARION MERRELL DOW 180MG N20062 002 DEC 27, 1991

>ADD> BC + 240MG N20062 003 DEC 27, 1991

>ADD> + 300MG N20062 004 DEC 27, 1991

>DLT> /300MG/ /N20062/004/ /DEC/27/1991/

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DILACOR XR

BC	RHONE POULENC RORER	180MG‡	N20092 002	MAY 29, 1992
BC		240MG‡	N20092 003	MAY 29, 1992
∂		120MG‡	N20092 001	MAY 29, 1992

INJECTABLE; INJECTION

CARDIZEM

	MARION MERRELL DOW	5MG/ML	N20027 001	OCT 24, 1991
		/25MG/VIAL/	/N20027/001/	/OCT/24,/1991/
		/50MG/VIAL/	/N20027/002/	/OCT/24,/1991/

DIPYRIDAMOLE

TABLET; ORAL

DIPYRIDAMOLE

AB	GENEVA	50MG‡	N87562 001	FEB 25, 1992
AB		75MG‡	N87561 001	FEB 25, 1992

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL

DISOPYRAMIDE PHOSPHATE

/B*/	/CHELSEA/	/EQ/100MG/BASE/	/N71020/001/	/DEC/01,/1986/
/B*/		/EQ/150MG/BASE/	/N71021/001/	/DEC/01,/1986/
/B*/	/INTERPHARM/	/EQ/100MG/BASE‡/	/N71190/001/	/JAN/15,/1987/
/B*/		/EQ/150MG/BASE‡/	/N71191/001/	/JAN/15,/1987/
∂	INTERPHARM	EQ 100MG BASE‡	N71190 001	JAN 15, 1987
∂		EQ 150MG BASE‡	N71191 001	JAN 15, 1987

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOPAMINE HCL

/AP/	/LYPHOMED/	/40MG/ML/	/N70058/001/	/MAR/20,/1985/
/AP/		/80MG/ML/	/N70059/001/	/MAR/20,/1985/
/AP/		/160MG/ML/	/N70364/001/	/DEC/04,/1985/
∂	LYPHOMED	40MG/ML	N70058 001	MAR 20, 1985
∂		80MG/ML	N70059 001	MAR 20, 1985
∂		160MG/ML	N70364 001	DEC 04, 1985

DOXAPRAM HYDROCHLORIDE

INJECTABLE; INJECTION

DOPRAM

AP	ROBINS	20MG/ML	N14879 001

DOXAPRAM HCL

AP	STERIS	20MG/ML‡	N73529 001 JAN 30, 1992

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

DOXYCYCLINE HYCLATE

/B*/	/INTERPHARM/	/EQ/50MG/BASE‡/	/N62763/001/	/SEP/02,/1988/
/B*/		/EQ/100MG/BASE‡/	/N62763/002/	/SEP/02,/1988/
∂	INTERPHARM	EQ 50MG BASE‡	N62763 001	SEP 02, 1988
∂		EQ 100MG BASE‡	N62763 002	SEP 02, 1988

TABLET; ORAL

DOXYCYCLINE HYCLATE

/B*/	/INTERPHARM/	/EQ/100MG/BASE‡/	/N62764/001/	/SEP/02,/1988/
∂	INTERPHARM	EQ 100MG BASE‡	N62764 001	SEP 02, 1988
>DLT >/AB/	/PARKE/DAVIS/	/EQ 100MG BASE/	/N62593/001/	/AUG/28,/1985/
∂	WARNER CHILCOTT	EQ 100MG BASE	N62593 001	AUG 28, 1985

DROPERIDOL

INJECTABLE; INJECTION

DROPERIDOL

/AP/	/SOLOPAK/	/2.5MG/ML/	/N71750/001/ /SEP/06,/1988/
∂ SOLOPAK		2.5MG/ML	N71750 001 SEP 06, 1988

ERGOLOID MESYLATES

TABLET; SUBLINGUAL

/ALKERGOT/

/AA/	/VITARINE/	/0.5MG/	/N85153/001/
/AA/		/1MG/	/N87417/001/
∂ VITARINE		0.5MG	N85153 001
∂		1MG	N87417 001

ERGOTAMINE TARTRATE

TABLET; SUBLINGUAL

/ERGOMAR/

/AA/	/FISONS/	/2MG/	/N87693/001/ /FEB/24,/1983/
∂ FISONS		2MG	N87693 001 FEB 24, 1983

ERYTHROMYCIN

SOLUTION; TOPICAL

>ADD>		SANSAC		
>ADD>	AT	OWEN GALDERMA	2%	N62522 001 JAN 24, 1985
>ADD>				
>DLT>		/SANSACNE/		
>DLT>	/AT/	/OWEN/GALDERMA/	/2%/	/N62522/001/ /JAN/24,/1985/
>DLT>				

TABLET, COATED PARTICLES; ORAL

PCE

ABBOTT	500MG	N50611 002 AUG 22, 1990

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

GENCEPT 0.5/35-21

AB	GENCON	0.035MG;0.5MG	N72692 001 FEB 28, 1992

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

GENCEPT 1/35-21

AB	GENCON	0.035MG;1MG	N72693 001 FEB 28, 1992

GENCEPT 10/11-21

AB	GENCON	0.035MG;0.5MG AND 1MG	N72694 001 FEB 28, 1992

TABLET; ORAL-28

GENCEPT 0.5/35-28

AB	GENCON	0.035MG;0.5MG	N72695 001 FEB 28, 1992

GENCEPT 1/35-28

AB	GENCON	0.035MG;1MG	N72696 001 FEB 28, 1992

GENCEPT 10/11-28

AB	GENCON	0.035MG;0.5MG AND 1MG	N72697 001 FEB 28, 1992

FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

PLENDIL

/MERCK/	/5MG/	/N19834/001/ /JUL/26,/1991/
MERCK	5MG	N19834 001 JUL 25, 1991
	/10MG/	/N19834/002/ /JUL/26,/1991/
	10MG	N19834 002 JUL 25, 1991

FENOPROFEN CALCIUM

CAPSULE; ORAL

FENOPROFEN CALCIUM

/AB/	/HALSEY/	/EQ 200MG BASE/	/N72355/001/ /JUL/05,/1988/
/AB/		/EQ 300MG BASE/	/N72356/001/ /JUL/05,/1988/
∂ HALSEY		EQ 200MG BASE	N72355 001 JUL 05, 1988
∂		EQ 300MG BASE	N72356 001 JUL 05, 1988

FENOPROFEN CALCIUM

TABLET; ORAL
FENOPROFEN CALCIUM

/AB/	/HALSEY/	/EQ 600MG BASE/	/N72357/001/ /JUL/05,/1988/
	∂ HALSEY	EQ 600MG BASE	N72357 001 JUL 05, 1988

FLUOCINONIDE

CREAM; TOPICAL
FLUOCINONIDE

AB	NMC	0.05%	N73085 001 FEB 14, 1992

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL
FLURAZEPAM HCL

/B*/	/PHARM/BASICS/	/15MG/	/N70562/001/ /JUL/09,/1987/
/B*/		/30MG/	/N70563/001/ /JUL/09,/1987/
	∂ PHARM BASICS	15MG	N70562 001 JUL 09, 1987
	∂	30MG	N70563 001 JUL 09, 1987

FOLIC ACID

TABLET; ORAL
FOLIC ACID

/AA/	/LILLY/	/1MG/	/N06135/003/
	∂ LILLY	1MG	N06135 003
/AA/	/VITARINE/	/1MG/	/N84472/001/
	∂ VITARINE	1MG	N84472 001

FUROSEMIDE

INJECTABLE; INJECTION
FUROSEMIDE

/AP/	/LYPHOMED/	/10MG/ML/	/N18507/001/ /JUL/30,/1982/
	∂ LYPHOMED	10MG/ML	N18507 001 JUL 30, 1982

FUROSEMIDE

TABLET; ORAL
FUROSEMIDE

/AB/	/CHELSEA/	/20MG/	/N18369/001/ /MAY/14,/1982/
/AB/		/40MG/	/N18369/002/ /MAY/14,/1982/
	∂ CHELSEA	20MG	N18369 001 MAY 14, 1982
	∂	40MG	N18369 002 MAY 14, 1982
/AB/	/VITARINE/	/40MG/	/N18750/002/ /JUL/30,/1984/
	∂ VITARINE	40MG	N18750 002 JUL 30, 1984

GLYBURIDE

TABLET; ORAL
GLUBATE

BX	HOECHST ROUSSEL	1.5MG	N20055 001 APR 17, 1992
BX		3MG	N20055 002 APR 17, 1992

GLYNASE

BX	UPJOHN	1.5MG	N20051 001 MAR 04, 1992
BX +		3MG	N20051 002 MAR 04, 1992

HALOPERIDOL

HYDRALAZINE HYDROCHLORIDE

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

> DLT >	/AB/	/ROYCE/	/0.5MG/	/N71722/001/ DEC/24,/1987/
> DLT >				
> DLT >	/AB/		/1MG/	/N71723/001/ DEC/24,/1987/
> DLT >				
> DLT >	/AB/		/2MG/	/N71724/001/ DEC/24,/1987/
> DLT >				
> DLT >	/AB/		/5MG/	/N71725/001/ DEC/24,/1987/
> DLT >				
> DLT >	/AB/		/10MG/	/N72121/001/ DEC/24,/1987/
> DLT >				
> DLT >	/AB/		/20MG/	/N72122/001/ DEC/24,/1987/
> DLT >				
> ADD >		ə ROYCE	0.5MG	N71722 001 DEC 24, 1987
> ADD >				
> ADD >		ə	1MG	N71723 001 DEC 24, 1987
> ADD >				
> ADD >		ə	2MG	N71724 001 DEC 24, 1987
> ADD >				
> ADD >		ə	5MG	N71725 001 DEC 24, 1987
> ADD >				
> ADD >		ə	10MG	N72121 001 DEC 24, 1987
> ADD >				
> ADD >		ə	20MG	N72122 001 DEC 24, 1987
> ADD >				

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN LOCK FLUSH

/AP/	/LUITPOLD/	/10 UNITS/ML/	/N89063/001/ OCT/09,/1985/
/AP/		/100 UNITS/ML/	/N89064/001/ OCT/09,/1985/
	ə LUITPOLD	10 UNITS/ML	N89063 001 OCT 09, 1985
	ə	100 UNITS/ML	N89064 001 OCT 09, 1985

HEPARIN SODIUM

/AP/	/LUITPOLD/	/1,000 UNITS/ML/	/N87452/001/ OCT/31,/1983/
	ə LUITPOLD	1,000 UNITS/ML	N87452 001 OCT 31, 1983

HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5%

/3/	/ABBOTT/	/10,000/UNITS/100ML/	/N18911/006/ JAN/30,/1985/
AP	ABBOTT	10,000 UNITS/100ML	N18911 006 JAN 30, 1985

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

APRESOLINE

/AP/	/CIBA/	/20MG/ML/	/N08303/003/
	CIBA	20MG/ML	N08303 003

HYDRALAZINE HCL;

/AP/	/LYPHOMED/	/20MG/ML/	/N89532/001/ AUG/11,/1987/
	ə LYPHOMED	20MG/ML	N89532 001 AUG 11, 1987

TABLET; ORAL

HYDRALAZINE HCL

/AB/	/VITARINE/	/50MG/	/N85088/001/
	ə VITARINE	50MG	N85088 001

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

/HYDRAL/

> DLT >				
> DLT >	/AB/	/SOLVAY/	/25MG;25MG/	/N87608/001/ FEB/08,/1982/
> DLT >				
> DLT >	/AB/		/50MG;50MG/	/N87213/001/ FEB/08,/1982/
> DLT >				
> DLT >	/AB/		/100MG;50MG/	/N87609/001/ FEB/08,/1982/
> DLT >				

HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE

> ADD >	AB	SOLVAY	25MG;25MG	N87608 001 FEB 08, 1982
> ADD >				
> ADD >	AB		50MG;50MG	N87213 001 FEB 08, 1982
> ADD >				
> ADD >		ə	100MG;50MG	N87609 001 FEB 08, 1982
> ADD >				

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

/HYDRAP-ES/

/BP/	/VITARINE/	/25MG;15MG;0.1MG/	/N84876/001/
	ə VITARINE	25MG;15MG;0.1MG	N84876 001

HYDRALAZINE HYDROCHLORIDE; RESERPINE

TABLET; ORAL

/DRALSERP/

/BP/	/VITARINE/	/25MG;0.1MG/	/N84617/001/
	ə VITARINE	25MG;0.1MG	N84617 001

HYDRALAZINE HYDROCHLORIDE; RESERPINE

TABLET; ORAL
SERPASIL-APRESOLINE
/BP/ /CIBA/ /25MG;0.1MG/ /N09296/004/
CIBA 25MG;0.1MG N09296,004

HYDROCHLOROTHIAZIDE

TABLET; ORAL
HYDROCHLOROTHIAZIDE
AB DANBURY 25MG¤ N81189 001
JAN 24, 1992
AB 100MG¤ N81190 001
JAN 24, 1992

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL
/HYDRO-SERP/25/
/BP/ /VITARINE/ /25MG;0.125MG/ /N84827/001/
∂ VITARINE 25MG;0.125MG N84827 001
/HYDRO-SERP/50/
/BP/ /VITARINE/ /50MG;0.125MG/ /N85213/001/
∂ VITARINE 50MG;0.125MG N85213 001

HYDROCHLOROTHIAZIDE; TRIAMTERENE

TABLET; ORAL
MAXZIDE-25
AB MYLAN 25MG;37.5MG N19129 003
MAY 13, 1988
TRIAMTERENE AND HYDROCHLOROTHIAZIDE
AB GENEVA 25MG;37.5MG¤ N73281 001
APR 30, 1992

HYDROCORTISONE

LOTION; TOPICAL
/CORT-DOME/
/BI/ /MILES/ /0.5%/ /N09895/003/
/BI/ /1%/ /N09895/001/
∂ MILES 0.5% N09895 003
∂ 1% N09895 001

HYDROCORTISONE

SOLUTION; TOPICAL
TEXACORT
GENDERM 2.5%¤ N81271 001
APR 17, 1992

TABLET; ORAL
> DLT > /HYCORTOLE/
> DLT > /∂/VITARINE/ /20MG/ /N80642/002/
HYDROCORTISONE
> ADD > ∂ EON LABS 20MG N80642 002

HYDROFLUMETHIAZIDE; RESERPINE

TABLET; ORAL
/HYDROFLUMETHIAZIDE/AND/RESERPINE/
/B*/ /PHARM/BASICS/ /50MG;0.125MG/ /N88195/001/
/OCT/26,/1983/
∂ PHARM BASICS 50MG;0.125MG N88195 001
OCT 26, 1983

HYDROXYAMPHETAMINE HYDROBROMIDE; TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC
PAREMYD
ALLERGAN 1%;0.25%¤ N19261 001
JAN 30, 1992

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL
HYDROXYZINE HCL
/B*/ /PHARM/BASICS/ /10MG/ /N89121/001/
/MAR/20,/1986/
/B*/ /25MG/ /N89122/001/
/MAR/20,/1986/
/B*/ /50MG/ /N89123/001/
/MAR/20,/1986/
∂ PHARM BASICS 10MG N89121 001
MAR 20, 1986
∂ 25MG N89122 001
MAR 20, 1986
∂ 50MG N89123 001
MAR 20, 1986

IBUPROFEN

ISOETHARINE HYDROCHLORIDE

IBUPROFEN

TABLET; ORAL
IBUPROFEN

/AB/	/SUPERPHARM/	/600MG/	/N70709/001/ /APR/25,/1986/		
	ə SUPERPHARM	600MG	N70709 001 APR 25, 1986		

IOFETAMINE HYDROCHLORIDE I-123

INJECTABLE; INJECTION
SPECTAMINE

	IMP	1 MCI/ML	N19432 001 DEC 24, 1987		
	/MEDI/PHYSICS/	/1/MCI/ML/	/N19432/001/ /DEC/24,/1987/		

IOVERSOL

INJECTABLE; INJECTION
OPTIRAY 300

	MALLINCKRODT	64%M	N19710 004 JAN 22, 1992		

OPTIRAY 350

	MALLINCKRODT	74%M	N19710 005 JAN 22, 1992		

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION
ISOETHARINE HCL

>DLT>	/AN/	/ARMOUR/	/0.125%/	/N87938/001/ /NOV/15,/1982/		
>DLT>	/AN/		/0.16%/	/N88470/001/ /MAR/14,/1984/		
>DLT>	/AN/		/0.2%/	/N88471/001/ /MAR/14,/1984/		
>DLT>	/AN/		/0.25%/	/N88472/001/ /MAR/14,/1984/		
>DLT>			/0.062%/	/N87937/001/ /NOV/15,/1982/		

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION
ISOETHARINE HCL

>ADD>	AN	ASTRA	0.125%	N87938 001 NOV 15, 1982		
>ADD>			0.062%	N87937 001 NOV 15, 1982		
>ADD>		ə	0.16%	N88470 001 MAR 14, 1984		
>ADD>		ə	0.2%	N88471 001 MAR 14, 1984		
>ADD>		ə	0.25%	N88472 001 MAR 14, 1984		
>ADD>	/AN/	/DEY/	/0.08%/	/N88187/001/ /DEC/03,/1982/		
	/AN/		/0.1%/	/N87389/001/		
	/AN/		/0.17%/	/N87390/001/		
	/AN/		/0.25%/	/N88188/001/ /DEC/03,/1982/		
	/AN/		/1%/	/N86763/001/		
		ə DEY	0.08%	N88187 001 DEC 03, 1982		
		ə	0.1%	N87389 001		
		ə	0.17%	N87390 001		
		ə	0.25%	N88188 001 DEC 03, 1982		
		ə	1%	N86763 001		

ISOETHARINE HCL S/F

>ADD>	AN	DEY	0.17%	N89819 001 NOV 22, 1988		
>DLT>			/0.17%/	/N89819/001/ /NOV/22,/1988/		

ISOPROTERENOL HYDROCHLORIDE

SOLUTION; INHALATION
ISOPROTERENOL HCL

	/AN/	/DEY/	/0.5%/	/N86764/001/ /JAN/04,/1982/		
		ə DEY	0.5%	N86764 001 JAN 04, 1982		

LACTULOSE

SYRUP; ORAL
LACTULOSE

>ADD>	AA	ROXANE LABS	10GM/15ML	N73591 001 MAY 29, 1992		

LACTULOSE

SYRUP; ORAL, RECTAL
LACTULOSE

>ADD>	AA	ROXANE LABS	10GM/15ML¤	N73590 001 MAY 29, 1992
>ADD>				

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION
LEUCOVORIN CALCIUM

/AP/	/LYPHOMED/	/EQ 50MG BASE/VIAL/	/N88939/001/ /DEC 01, 1986/
	∂ LYPHOMED	EQ 50MG BASE/VIAL	N88939 001 DEC 01, 1986

LEVODOPA

CAPSULE; ORAL
DOPAR

/+//P/AND/G/		/500MG/	/N16913/002/
		/100MG/	/N16913/003/
		/250MG/	/N16913/001/
	+ ROBERTS	500MG	N16913 002
		100MG	N16913 003
		250MG	N16913 001

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
LIDOCAINE HCL

	/INTL/MEDICATION/	/1GM/VIAL/	/N18543/001/
	∂ INTL MEDICATION	1GM/VIAL	N18543 001
		/2GM/VIAL/	/N18543/002/
	∂	2GM/VIAL	N18543 002

LIDOCAINE HCL 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	MCGAW	200MG/100ML¤	N19830 002 APR 08, 1992

LIDOCAINE HCL 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	MCGAW	400MG/100ML¤	N19830 003 APR 08, 1992

LIDOCAINE HCL 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	MCGAW	800MG/100ML¤	N19830 004 APR 08, 1992

LITHIUM CARBONATE

CAPSULE; ORAL
LITHIUM CARBONATE

/B*/	/PHARM/BASICS/	/300MG/	/N72542/001/ /FEB/01,/1989/
	∂ PHARM BASICS	300MG	N72542 001 FEB 01, 1989

LOMEFLOXACIN HYDROCHLORIDE

TABLET; ORAL
MAXAQUIN

	+ SEARLE	EQ 400MG BASE¤	N20013 001 FEB 21, 1992

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL
LOPERAMIDE HCL

AB	LEMMON	2MG¤	N73192 001 APR 30, 1992

LORAZEPAM

TABLET; ORAL
LORAZEPAM

/B*/	/PHARM/BASICS/	/1MG/	/N70539/001/ /DEC/22,/1986/
/B*/		/2MG/	/N70540/001/ /DEC/22,/1986/
	∂ PHARM BASICS	1MG	N70539 001 DEC 22, 1986
	∂	2MG	N70540 001 DEC 22, 1986

MECLOFENAMATE SODIUM

CAPSULE; ORAL
MECLOFENAMATE SODIUM

/B*/	/PHARM/BASICS/	/EQ/50MG/BASE/	/N71007/001/ /MAR/25,/1988/
/B*/		/EQ/100MG/BASE/	/N71008/001/ /MAR/25,/1988/
	∂ PHARM BASICS	EQ 50MG BASE	N71007 001 MAR 25, 1988
	∂	EQ 100MG BASE	N71008 001 MAR 25, 1988

MEGESTROL ACETATE

TABLET; ORAL
MEGESTROL ACETATE

/B*/	/PHARM/BASICS/	/20MG/	/N70646/001/	> DLT >			/N71275/001/
			/OCT/02,/1987/	> DLT >			/JUL/27,/1988/
/B*/		/40MG/	/N70647/001/	> DLT >	/AN/	/ARMOUR/ /0.4%/	/N71018/001/
			/OCT/02,/1987/	> DLT >			/JUL/27,/1988/
	∂ PHARM BASICS	20MG	N70646 001	> ADD >	AN	ASTRA 0.4%	N71275 001
			OCT 02, 1987	> ADD >			JUL 27, 1988
	∂	40MG	N70647 001	> ADD >	AN	0.6%	N71018 001
			OCT 02, 1987	> ADD >			JUL 27, 1988

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
MEPERIDINE HCL

AP	ABBOTT	10MG/ML	N88432 001			PROMETA	
			AUG 16, 1984		AN	MURO 5%¤	N73340 001
/AP/	/PARKE/DAVIS/	/50MG/ML/	/N80364/002/				MAR 30, 1992
/AP/		/100MG/ML/	/N80364/001/				
	∂ PARKE DAVIS	50MG/ML	N80364 002				
	∂	100MG/ML	N80364 001				
AP	STERIS	10MG/ML¤	N73443 001				
			MAR 17, 1992				
AP		50MG/ML¤	N73444 001				
			MAR 17, 1992				
AP		100MG/ML¤	N73445 001				
			MAR 17, 1992				

MEPROBAMATE

TABLET; ORAL
MEPROBAMATE

	∂ ELKINS SINN	200MG	N15426 002				
	∂	400MG	N15426 001				
/AA/	/PARKE/DAVIS/	/200MG/	/N84744/001/				
/AA/		/400MG/	/N84744/002/	> ADD >			
	∂ PARKE DAVIS	200MG	N84744 001	> ADD >			
	∂	400MG	N84744 002				
	/3/QUANTUM/PHARMICS/	/200MG/	/N15426/002/				
	/3/	/400MG/	/N15426/001/				

MESALAMINE

TABLET, DELAYED RELEASE; ORAL
ASACOL

+	P AND G	400MG¤	N19651 001				
			JAN 31, 1992				

METAPROTERENOL SULFATE

SOLUTION; INHALATION
METAPROTERENOL SULFATE

/AN/	/ARMOUR/	/0.4%/	/N71275/001/				
			/JUL/27,/1988/				
/AN/		/0.6%/	/N71018/001/				
			/JUL/27,/1988/				
AN	ASTRA	0.4%	N71275 001				
			JUL 27, 1988				
AN		0.6%	N71018 001				
			JUL 27, 1988				
			PROMETA				
AN	MURO	5%¤	N73340 001				
			MAR 30, 1992				

SYRUP; ORAL
METAPROTERENOL SULFATE

AA	BIOCRAFT	10MG/5ML¤	N72761 001
			FEB 27, 1992

TABLET; ORAL
METAPROTERENOL SULFATE

/B*/	/PHARM/BASICS/	/10MG/	/N71013/001/				
			/JAN/25,/1988/				
/B*/		/20MG/	/N71014/001/				
			/JAN/25,/1988/				
	∂ PHARM BASICS	10MG	N71013 001				
			JAN 25, 1988				
	∂	20MG	N71014 001				
			JAN 25, 1988				

METHOTREXATE SODIUM

TABLET; ORAL
METHOTREXATE

AB	MYLAN	EQ 2.5MG BASE¤	N81235 001				
			MAY 15, 1992				

METHYCLOTHIAZIDE

TABLET; ORAL
METHYCLOTHIAZIDE

/B*/	/PHARM/BASICS/	/5MG/	/N88745/001/				
			/MAR/21,/1985/				
	∂ PHARM BASICS	5MG	N88745 001				
			MAR 21, 1985				

METHYLDOPA

TABLET; ORAL
METHYLDOPA

/AB/	/PARKE/DAVIS/	/125MG/	/N70331/001/ /APR/15,/1986/
/AB/		/250MG/	/N70332/001/ /APR/15,/1986/
/AB/		/500MG/	/N70333/001/ /APR/15,/1986/
∂	PARKE DAVIS	125MG	N70331 001 APR 15, 1986
∂		250MG	N70332 001 APR 15, 1986
∂		500MG	N70333 001 APR 15, 1986

METHYLPREDNISOLONE

TABLET; ORAL
METHYLPREDNISOLONE

/BP/	/VITARINE/	/4MG/	/N87341/001/
∂	VITARINE	4MG	N87341 001

METOCLOPRAMIDE HYDROCHLORIDE

CONCENTRATE; ORAL
METOCLOPRAMIDE INTENSOL

	ROXANE	EQ 10MG BASE/ML¤	N72995 001 JAN 30, 1992

INJECTABLE; INJECTION
METOCLOPRAMIDE HCL

AP	CETUS BEN VENUE	EQ 10MG BASE/2ML¤	N72155 001 MAR 30, 1992
AP		EQ 10MG BASE/2ML¤	N72244 001 MAR 30, 1992
>ADD> AP		EQ 10MG BASE/2ML¤	N72247 001 MAY 18, 1992

>ADD>

TABLET; ORAL
METOCLOPRAMIDE HCL

/B*/	/INTERPHARM/	/EQ/10MG/BASE¤/	/N71213/001/ /SEP/24,/1986/
∂	INTERPHARM	EQ 10MG BASE¤	N71213 001 SEP 24, 1986

METOCLOPRAMIDE HYDROCHLORIDE

TABLET; ORAL
METOCLOPRAMIDE HCL

/B*/	/PHARM/BASICS/	/EQ/10MG/BASE/	/N70339/001/ /JUL/29,/1985/
∂	PHARM BASICS	EQ 10MG BASE	N70339 001 JUL 29, 1985

METOLAZONE

TABLET; ORAL
/DIULO/

/AB/	/SCHIAPPARELLI/SEARLE/	/2.5MG/	/N18535/001/
/AB/		/5MG/	/N18535/002/
/AB/		/10MG/	/N18535/003/
∂	SCHIAPPARELLI SEARLE	2.5MG	N18535 001
∂		5MG	N18535 002
∂		10MG	N18535 003

ZAROXOLYN

/AB/	/FISONS/	/2.5MG/	/N17386/001/
/AB/		/5MG/	/N17386/002/
/AB//+/		/10MG/	/N17386/003/
+	FISONS	10MG	N17386 003
		2.5MG	N17386 001
		5MG	N17386 002

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL
TOPROL XL

+	HASSLE	EQ 50MG TARTRATE¤	N19962 001 JAN 10, 1992
+		EQ 100MG TARTRATE¤	N19962 002 JAN 10, 1992
+		EQ 200MG TARTRATE¤	N19962 003 JAN 10, 1992

METRONIDAZOLE

INJECTABLE; INJECTION
METRONIDAZOLE

/AP/	/LYPHOMED/	/500MG/100ML/	/N70071/001/ /DEC/03,/1984/
∂	LYPHOMED	500MG/100ML	N70071 001 DEC 03, 1984

METRONIDAZOLE HYDROCHLORIDE

INJECTABLE; INJECTION
FLAGYL I.V.
/AP/ /SCHIAPPARELLI/SEARLE/EQ 500MG BASE/VIAL/ /N18353/001/
SCHIAPPARELLI SEARLE EQ 500MG BASE/VIAL N18353 001

METRONIDAZOLE HCL;
/AP/ /LYPHOMED/ /EQ 500MG BASE/VIAL/ /N70295/001/ /OCT 15, 1985/
∂ LYPHOMED EQ 500MG BASE/VIAL N70295 001 OCT 15, 1985

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL
MINOCYCLINE HCL
AB BIOCRAFT EQ 50MG BASE¤ N63011 001 MAR 02, 1992
AB EQ 100MG BASE¤ N63009 001 MAR 02, 1992

MINOXIDIL

TABLET; ORAL
MINOXIDIL
/B*/ /PHARM BASICS/ /2.5MG/ /N71537/001/ /DEC 16, 1988/
∂ PHARM BASICS 2.5MG N71537 001 DEC 16, 1988
/AB/ /ROYCE/ /2.5MG/ /N71799/001/ /NOV 10, 1987/
/AB/ /10MG/ /N71796/001/ /NOV 10, 1987/
∂ ROYCE 2.5MG N71799 001 NOV 10, 1987
∂ 10MG N71796 001 NOV 10, 1987

MIVACURIUM CHLORIDE

INJECTABLE; INJECTION
MIVACRON
BURROUGHS WELLCOME EQ 2MG BASE/ML¤ N20098 001 JAN 22, 1992

MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER
BURROUGHS WELLCOME EQ 0.5MG BASE/ML¤ N20098 002 JAN 22, 1992
EQ 50MG BASE/100ML¤ N20098 003 JAN 22, 1992

NAFARELIN ACETATE

SPRAY, METERED; NASAL
SYNAREL
SYNTEX EQ 0.2MG BASE/INH¤ N20109 001 FEB 26, 1992

NIACIN

TABLET; ORAL
NIACIN
AA WOCKHARDT LTD 500MG¤ N81134 001 APR 28, 1992

NICARDIPINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
CARDENE SR
+ SYNTEX 30MG¤ N20005 001 FEB 21, 1992
+ 45MG¤ N20005 002 FEB 21, 1992
+ 60MG¤ N20005 003 FEB 21, 1992

INJECTABLE; INJECTION
CARDENE
DUPONT MERCK 2.5MG/ML¤ N19734 001 JAN 30, 1992

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL
NICOTROL
+ KABI 5MG/16HR¤ N20150 001 APR 22, 1992
+ 10MG/16HR¤ N20150 002 APR 22, 1992
+ 15MG/16HR¤ N20150 003 APR 22, 1992

PROSTEP
+ ELAN 11MG/24HR¤ N19983 001 JAN 28, 1992
+ 22MG/24HR¤ N19983 002 JAN 28, 1992

NIFEDIPINE

CAPSULE; ORAL
NIFEDIPINE

AB	NOVOPHARM	10MG¤	N72651 001 FEB 19, 1992
AB	SCHERER	20MG¤	N74045 001 APR 30, 1992

NITROFURANTOIN

TABLET; ORAL
NITROFURANTOIN

/AB/	/VITARINE/	/50MG/	/N80043/001/
/AB/		/100MG/	/N80043/002/
	∂ VITARINE	50MG	N80043 001
	∂	100MG	N80043 002

NITROGLYCERIN

INJECTABLE; INJECTION
NITROGLYCERIN

/AP/	/LUITPOLD/	/5MG/ML/	/N71492/001/ /MAY/24,/1988/
	∂ LUITPOLD	5MG/ML	N71492 001 MAY 24, 1988

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL
NORTRIPTYLINE HCL

AB	DANBURY	EQ 10MG BASE¤	N73553 001 MAR 30, 1992
AB		EQ 25MG BASE¤	N73554 001 MAR 30, 1992
AB		EQ 50MG BASE¤	N73555 001 MAR 30, 1992
AB		EQ 75MG BASE¤	N73556 001 MAR 30, 1992

PAMELOR

AB	SANDOZ	EQ 10MG BASE	N18013 001
AB		EQ 25MG BASE	N18013 002
AB		EQ 50MG BASE	N18013 004
AB +		EQ 75MG BASE	N18013 003
/BD/		/EQ/10MG/BASE/	/N18013/001/
/BD/		/EQ/25MG/BASE/	/N18013/002/

NYSTATIN

TABLET; ORAL
NYSTATIN

/AA/	/CHELSEA/	/500,000 UNITS/	/N62402/001/ /DEC/16,/1982/
	∂ CHELSEA	500,000 UNITS	N62402 001 DEC 16, 1982

TABLET; VAGINAL
NYSTATIN

/AT/	/VITARINE/	/100,000 UNITS/	/N61965/001/
	∂ VITARINE	100,000 UNITS	N61965 001

OFLOXACIN

INJECTABLE; INJECTION
FLOXIN

JOHNSON RW	20MG/ML¤	N20087 002 MAR 31, 1992
	40MG/ML¤	N20087 003 MAR 31, 1992

FLOXIN IN DEXTROSE 5%

JOHNSON RW	400MG/100ML¤	N20087 001 MAR 31, 1992

FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER

JOHNSON RW	4MG/ML¤	N20087 004 MAR 31, 1992
	400MG/100ML¤	N20087 005 MAR 31, 1992

OXAZEPAM

CAPSULE; ORAL
OXAZEPAM

/B*/	/CHELSEA/	/10MG/	/N71661/001/ /MAR/02,/1988/
/B*/		/15MG/	/N71662/001/ /MAR/02,/1988/
/B*/		/30MG/	/N71663/001/ /MAR/02,/1988/

OXYBUTYNIN CHLORIDE

TABLET; ORAL
OXYBUTYNIN CHLORIDE

/B*/	/PHARM/BASICS/	/5MG/	/N70746/001/	
			/MAR/10,/1988/	
	∂ PHARM BASICS	5MG	N70746 001	
			MAR 10, 1988	

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION
PENICILLIN G POTASSIUM

/AP/	/PARKE/DAVIS/	/1,000,000 UNITS/VIAL/	/N62003/001/
/AP/		/5,000,000 UNITS/VIAL/	/N62003/002/
	∂ PARKE DAVIS	1,000,000 UNITS/VIAL	N62003 001
	∂	5,000,000 UNITS/VIAL	N62003 002

PENICILLIN V POTASSIUM

POWDER FOR RECONSTITUTION; ORAL
/PENAPAR-VK/

/AA/	/PARKE/DAVIS/	/EQ 125MG BASE/5ML/	/N62002/001/
/AA/		/EQ 250MG BASE/5ML/	/N62002/002/
	∂ PARKE DAVIS	EQ 125MG BASE/5ML	N62002 001
	∂	EQ 250MG BASE/5ML	N62002 002

TABLET; ORAL
/PENAPAR-VK/

/AA/	/PARKE/DAVIS/	/EQ 250MG BASE/	/N62001/001/
/AA/		/EQ 500MG BASE/	/N62001/002/
	∂ PARKE DAVIS	EQ 250MG BASE	N62001 001
	∂	EQ 500MG BASE	N62001 002

PERPHENAZINE

TABLET; ORAL
PERPHENAZINE

/B*/	/CHELSEA/	/8MG/	/N89700/001/
			/DEC/23,/1987/

PHENDIMETRAZINE TARTRATE

TABLET; ORAL
/OBEZINE/

/AA/	/PHARM/BASICS/	/35MG/	/N83805/001/
/AA/		/35MG/	/N84398/001/
/AA/		/35MG/	/N84399/001/

PHENDIMETRAZINE TARTRATE

TABLET; ORAL
PHENDIMETRAZINE TARTRATE

AA	PHARM BASICS	35MG	N84399 001
	∂	35MG	N83805 001
	∂	35MG	N84398 001

PHENYLBUTAZONE

CAPSULE; ORAL
/AZOLID/

/AA/	/RHONE/POULENC/RORER//100MG/		/N87260/001/
	∂ RHONE POULENC RORER	100MG	N87260 001

TABLET; ORAL
/AZOLID/

/AA/	/RHONE/POULENC/RORER//100MG/		/N87091/001/
	∂ RHONE POULENC RORER	100MG	N87091 001

PHENYTOIN SODIUM, PROMPT

CAPSULE; ORAL
/PHENYTOIN/SODIUM/

/BX/	/CHELSEA/	/100MG/	/N85894/001/
	∂ CHELSEA	100MG	N85894 001

PIROXICAM

CAPSULE; ORAL
FELDENE

>ADD>	AB	PFIZER	10MG	N18147 002
>ADD>				APR 06, 1982
>ADD>	AB	+	20MG	N18147 003
>ADD>				APR 06, 1982
>ADD>		PIROXICAM		
>ADD>	AB	SCHIAPPARELLI SEARLE	10MG*	N74036 001
>ADD>				MAY 29, 1992
>ADD>	AB		20MG*	N74036 002
>ADD>				MAY 29, 1992

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

POWDER FOR RECONSTITUTION; ORAL

	CO-LAV			
AA	COPLEY	240GM/BOT;2.98GM/BOT;6.72GM/BOT; 5.84GM/BOT;22.72GM/BOT¤	N73428 001	JAN 28, 1992
	GO-EVAC			
AA	COPLEY	236MG/BOT;2.97GM/BOT;6.74GM/BOT; 5.86GM/BOT;22.74GM/BOT¤	N73433 001	APR 28, 1992

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

		K-LEASE			
AB		ADRIA	8MEQ¤	N73398 001	JAN 28, 1992
		MICRO-K			
AB		ROBINS	8MEQ	N18238 001	

TABLET, EXTENDED RELEASE; ORAL

		KLOTRIX			
>ADD>	BC	APOTHECON	10MEQ	N17850 001	
>DLT>	/BC/	/MEAD/JOHNSON/	/10MEQ/	/N17850/001/	

PRAZEPAM

CAPSULE; ORAL

		CENTRAX			
/AB/		/PARKE/DAVIS/	/5MG/	/N18144/001/	
/AB/	/+/		/10MG/	/N18144/002/	
	+	PARKE DAVIS	10MG	N18144 002	
			5MG	N18144 001	
		/PRAZEPAM/			
/B*/		/PHARM/BASICS/	/5MG/	/N70427/001/	NOV/06,/1987/
/B*/			/10MG/	/N70428/001/	NOV/06,/1987/
	ə	PHARM BASICS	5MG	N70427 001	NOV 06, 1987
	ə		10MG	N70428 001	NOV 06, 1987

PRAZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

	MINIPRESS XL			
	+ PFIZER	2.5MG¤	N19775 001	JAN 29, 1992
	+	5MG¤	N19775 002	JAN 29, 1992

PREDNISOLONE

TABLET; ORAL

	PREDNISOLONE			
>DLT> /BX/	/HEATHER/	/5MG/		/N80326/001/
>ADD>	ə HEATHER	5MG		N80326 001
/BX/	/VITARINE/	/5MG/		/N84773/001/
	ə VITARINE	5MG		N84773 001

PREDNISONE

TABLET; ORAL

	PREDNISONE			
AB	RICHLYN	5MG		N80782 001
/BX/		/5MG/		/N80782/001/
/BX/	/VITARINE/	/5MG/		/N84774/001/
	ə VITARINE	5MG		N84774 001

PROCAINAMIDE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

	PROCAINAMIDE HCL			
/AB/	/BOLAR/	/250MG/	/N88533/001/	/DEC/03,/1984/
/AB/		/500MG/	/N88534/001/	/DEC/03,/1984/
/AB/		/750MG/	/N88535/001/	/NOV/03,/1984/
	ə BOLAR	250MG	N88533 001	DEC 03, 1984
	ə	500MG	N88534 001	DEC 03, 1984
	ə	750MG	N88535 001	NOV 03, 1984

PROCAINE HYDROCHLORIDE; TETRACYCLINE HYDROCHLORIDE

INJECTABLE; INJECTION

ACHROMYCIN

AP	LEDERLE	40MG/VIAL;100MG/VIAL	N50267 002
AP		40MG/VIAL;100MG/VIAL	N50276 001
AP		40MG/VIAL;250MG/VIAL	N50267 003

TETRACYN

AP	PFIZER	40MG/VIAL;250MG/VIAL	N60285 003
∂		40MG/VIAL;100MG/VIAL	N60285 002

PROCHLORPERAZINE MALEATE

TABLET; ORAL

COMPAZINE

/AB/	/SKF/	/EQ 5MG BASE/	/N10571/001/
/AB/		/EQ 10MG BASE/	/N10571/002/
/AB/#/		/EQ 25MG BASE/	/N10571/003/
+	SKF	EQ 25MG BASE	N10571 003
		EQ 5MG BASE	N10571 001
		EQ 10MG BASE	N10571 002

/PROCHLORPERAZINE/MALEATE/

/B*/	/DURAMED/	/EQ/5MG/BASE/	/N89484/001/ /JAN/20,/1987/
/B*/		/EQ/10MG/BASE/	/N89485/001/ /JAN/20,/1987/
/B*/		/EQ/25MG/BASE/	/N89486/001/ /JAN/20,/1987/
∂	DURAMED	EQ 5MG BASE	N89484 001 JAN 20, 1987
∂		EQ 10MG BASE	N89485 001 JAN 20, 1987
∂		EQ 25MG BASE	N89486 001 JAN 20, 1987

PROMETHAZINE HYDROCHLORIDE

TABLET; ORAL

PROMETHAZINE HCL

/BP/	/VITARINE/	/25MG/	/N85146/001/
/BP/		/50MG/	/N85146/002/
∂	VITARINE	25MG	N85146 001
∂		50MG	N85146 002

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

PROPOXYPHENE HCL

/AA/	/VITARINE/	/32MG/	/N84014/001/
/AA/		/65MG/	/N83688/001/
/AA/		/65MG/	/N83870/002/
/AA/		/65MG/	/N86495/001/
∂	VITARINE	32MG	N84014 001
∂		65MG	N83688 001
∂		65MG	N83870 002
∂		65MG	N86495 001

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HCL

/AB/	/SUPERPHARM/	/10MG/	/N71515/001/ /JUN/08,/1988/
/AB/		/20MG/	/N71516/001/ /JUN/08,/1988/
∂	SUPERPHARM	10MG	N71515 001 JUN 08, 1988
∂		20MG	N71516 001 JUN 08, 1988

PROTIRELIN

INJECTABLE; INJECTION

RELEFACT TRH

>ADD >	AP	FERRING	0.5MG/ML	N18087 001
>DLT >/	AP/	/HOECHST/ROUSSEL/	/0.5MG/ML/	/N18087/001/

PYRIDOXINE HYDROCHLORIDE

INJECTABLE; INJECTION

PYRIDOXINE HCL

/AP/	/LUITPOLD/	/100MG/ML/	/N80669/001/
∂	LUITPOLD	100MG/ML	N80669 001

QUINETHAZONE; RESERPINE

/TABLET;/ORAL/

/HYDROMOX/R/

/LEDERLE/	/50MG;0.125MG/	/N13927/001/
∂ LEDERLE	50MG;0.125MG	N13927 001

QUINIDINE SULFATE

TABLET; ORAL
QUINIDINE SULFATE
∂ ELKINS SINN 200MG N83622 001
/∂/QUANTUM/PHARMICS/ /200MG/ /N83622/001/

RAUWOLFIA SERPENTINA

TABLET; ORAL
/RAUVERID/
/BP/ /FOREST/PHARMS/ /50MG/ /N09255/008/
WOLFINA
∂ FOREST PHARMS 50MG N09255 008

RESERPINE

TABLET; ORAL
RESERPINE
> ADD > BP EON LABS 0.1MG N09838 001
> ADD > BP 0.25MG N09838 002
> DLT > /BP/ /VITARINE/ /0.1MG/ /N09838/001/
> DLT > /BP/ /0.25MG/ /N09838/002/

SODIUM LACTATE

INJECTABLE; INJECTION
SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER
AP MCGAW 1.87GM/100ML¤ N20004 001 APR 21, 1992

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION
NITROPRESS
AP ABBOTT 25MG/ML N71961 001 AUG 01, 1988
SODIUM NITROPRUSSIDE
AP GENSIA 25MG/ML¤ N73465 001 MAR 30, 1992

SODIUM POLYSTYRENE SULFONATE

SUSPENSION; ORAL, RECTAL
SODIUM POLYSTYRENE SULFONATE
/AA/ /ROXANE/ /15GM/60ML/ /N88453/001/ /NOV/17/1983/
∂ ROXANE 15GM/60ML N88453 001 NOV 17, 1983

SODIUM THIOSULFATE

INJECTABLE; INJECTION
SODIUM THIOSULFATE
DEPT ARMY 250MG/ML¤ N20166 001 FEB 14, 1992

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION
SUCCINYLCHOLINE CHLORIDE
> DLT > /INTL/MEDICATION/ /100MG/VIAL/ /N85400/001/ /FEB/04/1982/
> DLT >
> ADD > ∂ INTL MEDICATION 100MG/VIAL N85400 001 FEB 04, 1982
> ADD >

/SULFABENZAMIDE;/SULFACETAMIDE;/SULFATHIAZOLE/

/CREAM;/VAGINAL/
/SULTRIN/
/JOHNSON/RW/ /3.75;2.86;3.42%/ /N05794/001/

/TABLET;/VAGINAL/
/SULTRIN/
/JOHNSON/RW/ /184MG;143.75MG;172.5MG/ /N05794/002/

> DLT > /TRIPLE/SULFA/
> DLT > /∂/FOUGERA/ /184MG;143.75MG;172.5MG/ /N88463/001/ /JAN/03/1985/
> DLT >
> DLT > /∂/PHARMADERM/ /184MG;143.75MG;172.5MG/ /N88462/001/ /JAN/03/1985/

/SULFABENZAMIDE;/SULFACETAMIDE;/SULFATHIAZOLE;/UREA/

/CREAM;/VAGINAL/
/GYNE-SULF/
/AA/ /G/AND/H/ /3.75;2.86;3.42;0.64%/ /N88607/001/ /JUN/09/1986/

/SULFABENZAMIDE;/SULFACETAMIDE;/SULFATHIAZOLE;/UREA/

/CREAM;/VAGINAL/
/TRIPLE SULFA/

/AT/	/CLAY/PARK/	/3.72;2.862;3.422;0.642/	/N87285/001/	/NOV/15/1982/
/AT/	/FOUGERA/	/3.72;2.862;3.422;0.642/	/N86424/001/	
/AT/	/NMC/	/3.72;2.862;3.422;0.642/	/N87864/001/	/SEP/01/1982/
/AT/	/PHARMADERM/	/3.72;2.862;3.422;0.642/	/N87887/001/	/JUL/23/1982/

/VAGILIA/

/AT/	/LEMMON/	/3.72;2.862;3.422;0.642/	/N88821/001/	/NOV/09/1987/

SULFAMETHIZOLE

TABLET; ORAL
/PROKLAR/

/AB/	/FOREST/PHARMS/	/500MG/	/N80273/001/
	∂ FOREST PHARMS	500MG	N80273 001

THIOSULFIL

/AB/	/WYETH/AYERST/	/500MG/	/N08565/004/
	+ WYETH AYERST	500MG	N08565 004

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION
SULFAMETHOXAZOLE AND TRIMETHOPRIM

AP	CETUS BEN VENUE	80MG/ML;16MG/ML¤	N72383 001 APR 29, 1992

TABLET; ORAL
SULFAMETHOXAZOLE AND TRIMETHOPRIM

/AB/	/INTERPHARM/	/400MG;80MG/	/N71299/001/ /OCT/27/1987/
/AB/		/800MG;160MG/	/N71300/001/ /OCT/27/1987/
B*	INTERPHARM	400MG;80MG	N71299 001 OCT 27, 1987
B*		800MG;160MG	N71300 001 OCT 27, 1987
/AB/	/MARTEC/	/400MG;80MG/	/N72408/001/ /DEC/07/1988/
	∂ MARTEC	400MG;80MG	N72408 001 DEC 07, 1988

SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL
SULFAMETHOXAZOLE AND TRIMETHOPRIM

/B*/	/PHARM/BASICS/	/400MG;80MG/	/N70203/001/ /NOV/08/1985/
/B*/		/800MG;160MG/	/N70204/001/ /NOV/08/1985/
	∂ PHARM BASICS	400MG;80MG	N70203 001 NOV 08, 1985
	∂	800MG;160MG	N70204 001 NOV 08, 1985

SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH

/AB/	/MARTEC/	/800MG;160MG/	/N72417/001/ /DEC/07/1988/
	∂ MARTEC	800MG;160MG	N72417 001 DEC 07, 1988

SULFISOXAZOLE

TABLET; ORAL
/SULFALAR/

/AB/	/PARKE/DAVIS/	/500MG/	/N84955/001/
	∂ PARKE DAVIS	500MG	N84955 001

SULFISOXAZOLE

/AB/	/WEST/WARD/	/500MG/	/N80379/001/
	∂ WEST WARD	500MG	N80379 001

SULINDAC

TABLET; ORAL
SULINDAC

AB	LEMMON	150MG¤	N72972 001 FEB 28, 1992
AB		200MG¤	N72973 001 FEB 28, 1992

TALBUTAL

/TABLET;/ORAL/
/LOTUSATE/

	/STERLING/	/120MG/	/N09410/005/
	∂ STERLING	120MG	N09410 005

TEMAFLOXACIN HYDROCHLORIDE

TABLET; ORAL
OMNIFLOX

+ ABBOTT	EQ 600MG BASE¤	N20043 004	
		JAN 30,' 1992	
	EQ 400MG BASE¤	N20043 003	
		JAN 30, 1992	

TEMAZEPAM

CAPSULE; ORAL
TEMAZEPAM

/B*/ /PHARM/BASICS/	/15MG/	/N70489/001/	
		/JUL/07,/1986/	
/B*/	/30MG/	/N70490/001/	
		/JUL/07,/1986/	
∂ PHARM BASICS	15MG	N70489 001	
		JUL 07, 1986	
∂	30MG	N70490 001	
		JUL 07, 1986	

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION
DELATESTRYL

AO GYNEX	200MG/ML	N09165 003	
∂	200MG/ML	N09165 001	
/AO/ /SQUIBB/	/200MG/ML/	/N09165/003/	
/∂/	/200MG/ML/	/N09165/001/	

TETRACYCLINE

SYRUP; ORAL
/BIOCYCLINE/

/AB/ /BARRE/	/EQ 125MG HCL/5ML/	/N60633/001/	

TETRACYCLINE

AB BARRE	EQ 125MG HCL/5ML	N60633 001	

TETRACYCLINE HYDROCHLORIDE

/INJECTABLE;/INJECTION/
/ACHROMYCIN/

/AP/ /LEDERLE/	/100MG/VIAL/	/N50267/002/	
/AP/	/100MG/VIAL/	/N50276/001/	
/AP/	/250MG/VIAL/	/N50267/003/	
/TETRACYN/			
/AP/ /PFIZER/	/250MG/VIAL/	/N60285/003/	
/∂/	/100MG/VIAL/	/N60285/002/	

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL
SOMOPHYLLIN-CRT

/BC/	/FISONS/	/50MG/		/N87763/001/ /FEB/27,/1985/
/BC/		/100MG/		/N87194/001/
/BC/		/200MG/		/N88382/001/ /FEB/27,/1985/
/BC/		/250MG/		/N87193/001/
/BC/		/300MG/		/N88383/001/ /FEB/27,/1985/
BC	GRAHAM LABS	50MG		N87763 001 FEB 27, 1985
BC		100MG		N87194 001
BC		200MG		N88382 001 FEB 27, 1985
BC		250MG		N87193 001
BC		300MG		N88383 001 FEB 27, 1985

THEO-24

/BC/	/SEARLE/	/100MG/		/N87942/001/ /AUG/22,/1983/
/BC/		/200MG/		/N87943/001/ /AUG/22,/1983/
/BC/		/300MG/		/N87944/001/ /AUG/22,/1983/
		/400MG¤/		/N81034/001/ /FEB/28,/1992/
BC	WHITBY PHARMS	100MG		N87942 001 AUG 22, 1983
BC		200MG		N87943 001 AUG 22, 1983
BC		300MG		N87944 001 AUG 22, 1983
		400MG¤		N81034 001 FEB 28, 1992

TABLET, EXTENDED RELEASE; ORAL
T-PHYL

>ADD> BC	PURDUE FREDERICK	200MG		N88253 001 AUG 17, 1983
>ADD>				
>DLT>	/THEOCONTIN/			
>DLT> /BC/	/PURDUE/FREDERICK/	/200MG/		/N88253/001/ /AUG/17,/1983/
>DLT>				

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

THIAMINE HCL

/AP/	/LUITPOLD/	/100MG/ML/	/N80667/001/	
	∂ LUITPOLD	100MG/ML	N80667 001	
/AP/	/PARKE/DAVIS/	/100MG/ML/	/N80770/001/	
	∂ PARKE DAVIS	100MG/ML	N80770 001	

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

THIORIDAZINE HCL

/AB/	/PAR/	/150MG/	/N89764/001/ /FEB/09,/1988/	
/AB/		/200MG/	/N89765/001/ /FEB/09,/1988/	
	∂ PAR	150MG	N89764 001 FEB 09, 1988	
	∂	200MG	N89765 001 FEB 09, 1988	

TIMOLOL MALEATE

TABLET; ORAL

TIMOLOL MALEATE

/B*/	/PHARM/BASICS/	/5MG/	/N72001/001/ /JAN/10,/1989/	
/B*/		/10MG/	/N72002/001/ /JAN/10,/1989/	
/B*/		/20MG/	/N72003/001/ /JAN/10,/1989/	
	∂ PHARM BASICS	5MG	N72001 001 JAN 10, 1989	
	∂	10MG	N72002 001 JAN 10, 1989	
	∂	20MG	N72003 001 JAN 10, 1989	

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

TOBRAMYCIN SULFATE

>ADD> AP	ABBOTT	EQ 40MG BASE/ML*	N63116 001 MAY 18, 1992	
>ADD> AP	GENSIA	EQ 40MG BASE/ML*	N63100 001 JAN 30, 1992	

TOLAZAMIDE

TABLET; ORAL

TOLAZAMIDE

/AB/	/INTERPHARM/	/250MG/	/N71270/001/ /SEP/23,/1986/	
/AB/		/500MG/	/N71271/001/ /SEP/23,/1986/	
B*	INTERPHARM	250MG	N71270 001 SEP 23, 1986	
B*		500MG	N71271 001 SEP 23, 1986	
/B*/	/PHARM/BASICS/	/100MG/	/N71355/001/ /JAN/11,/1988/	
/B*/		/250MG/	/N70168/001/ /APR/02,/1986/	
/B*/		/500MG/	/N70169/001/ /APR/02,/1986/	
	∂ PHARM BASICS	100MG	N71355 001 JAN 11, 1988	
	∂	250MG	N70168 001 APR 02, 1986	
	∂	500MG	N70169 001 APR 02, 1986	

TOLBUTAMIDE

TABLET; ORAL

TOLBUTAMIDE

/AB/	/PARKE/DAVIS/	/500MG/	/N86047/001/	
	∂ PARKE DAVIS	500MG	N86047 001	

TOLMETIN SODIUM

CAPSULE; ORAL

TOLMETIN SODIUM

AB	BAKER CUMMINS	EQ 400MG BASE*	N73392 001 JAN 24, 1992	
AB	GENEVA	EQ 400MG BASE*	N73462 001 APR 30, 1992	
>ADD> AB	LEMMON	EQ 400MG BASE*	N73519 001 MAY 29, 1992	
>ADD> AB	PUREPAC	EQ 400MG BASE*	N73308 001 JAN 24, 1992	

TRAZODONE HYDROCHLORIDE

TABLET; ORAL
TRAZODONE HCL

/B*/	/PHARM/BASICS/	/50MG/	/N70491/001/ APR/29,/1987/			
/B*/		/100MG/	/N70492/001/ APR/29,/1987/			
∂	PHARM BASICS	50MG	N70491 001 APR 29, 1987			
∂		100MG	N70492 001 APR 29, 1987			

TRICHLORMETHIAZIDE

TABLET; ORAL
TRICHLORMETHIAZIDE

/BP/	/VITARINE/	/4MG/	/N86171/001/			
∂	VITARINE	4MG	N86171 001			

TRIMIPRAMINE MALEATE

CAPSULE; ORAL
SURMONTIL

/AB/	/WYETH/AYERST/	/EQ 25MG BASE/	/N16792/001/	> ADD >		
/AB/		/EQ 50MG BASE/	/N16792/002/	> ADD >		
/AB//+/		/EQ 100MG BASE/	/N16792/003/ SEP/15,/1982/	> ADD >		
+	WYETH AYERST	EQ 100MG BASE	N16792 003 SEP 15, 1982	> ADD >		
		EQ 25MG BASE	N16792 001			
		EQ 50MG BASE	N16792 002			

/TRIMIPRAMINE/MALEATE/

/B*/	/PHARM/BASICS/	/EQ/25MG/BASE/	/N71283/001/ DEC/08,/1987/			
/B*/		/EQ/50MG/BASE/	/N71284/001/ DEC/08,/1987/			
/B*/		/EQ/100MG/BASE/	/N71285/001/ DEC/08,/1987/			
∂	PHARM BASICS	EQ 25MG BASE	N71283 001 DEC 08, 1987			
∂		EQ 50MG BASE	N71284 001 DEC 08, 1987			
∂		EQ 100MG BASE	N71285 001 DEC 08, 1987			

TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE;SULFATHIAZOLE)

CREAM; VAGINAL

	GYNE-SULF		
AT	G AND W	3.7%;2.86%;3.42%	N88607 001 JUN 09, 1986
	SULTRIN		
AT	JOHNSON RW	3.7%;2.86%;3.42%	N05794 001
	TRIPLE SULFA		
AT	CLAY PARK	3.7%;2.86%;3.42%	N87285 001 NOV 15, 1982
AT	FOUGERA	3.7%;2.86%;3.42%	N86424 001
AT	NMC	3.7%;2.86%;3.42%	N87864 001 SEP 01, 1982
	TRYSUL		
AT	SAVAGE	3.7%;2.86%;3.42%	N87887 001 JUL 23, 1982
	VAGILIA		
∂	LEMMON	3.7%;2.86%;3.42%	N88821 001 NOV 09, 1987

TABLET; VAGINAL
SULTRIN

JOHNSON RW	184MG;143.75MG;172.5MG	N05794 002
TRIPLE SULFA		
∂ FOUGERA	184MG;143.75MG;172.5MG	N88463 001 JAN 03, 1985
∂ PHARMADERM	184MG;143.75MG;172.5MG	N88462 001 JAN 03, 1985

TRISULFAPYRIMIDINES

SUSPENSION; ORAL
/SULFALOID/

/AB/	/FOREST/PHARMS/	/500MG/5ML/	/N80100/001/			
∂	FOREST PHARMS	500MG/5ML	N80100 001			

VECURONIUM BROMIDE

INJECTABLE; INJECTION
NORCURON

	ORGANON	20MG/VIAL*	*N18776 003 JAN 03, 1992*

VERAPAMIL HYDROCHLORIDE

WARFARIN SODIUM

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
VERELAN

+	ELAN	180MG	N19614 003 JAN 09, 1992

TABLET; ORAL
VERAPAMIL HCL

/B*/	/CHELSEA/	/80MG/	/N70421/001/ /SEP/17,/1986/
/B*/		/120MG/	/N70422/001/ /SEP/17,/1986/
/AB/	/PARKE/DAVIS/	/80MG/	/N70340/001/ /AUG/20,/1986/
/AB/		/120MG/	/N70341/001/ /AUG/20,/1986/
	∂ PARKE DAVIS	80MG	N70340 001 AUG 20, 1986
	∂	120MG	N70341 001 AUG 20, 1986

VITAMIN A

CAPSULE; ORAL
AQUASOL A

>ADD>	AA	ASTRA	50,000 USP UNITS	N83080 001
>ADD>			25,000 USP UNITS	N83080 002
>DLT>/	AA/	/USV/	/50,000 USP UNITS/	/N83080/001/
>DLT>			/25,000/USP/UNITS/	/N83080/002/

VITAMIN A PALMITATE

CAPSULE; ORAL
VITAMIN A

	∂ ELKINS SINN	EQ 50,000 UNITS BASE	N85479 001
	/∂/QUANTUM/PHARMICS/	/EQ/50,000/UNITS/BASE/	/N85479/001/

WARFARIN SODIUM

TABLET; ORAL
/WARFARIN/SODIUM/

/B*/	/PHARM/BASICS/	/2MG/	/N88719/001/ /JUN/27,/1985/
/B*/		/2.5MG/	/N88720/001/ /AUG/06,/1985/
/B*/		/5MG/	/N88721/001/ /JUL/02,/1985/

WARFARIN SODIUM

TABLET; ORAL
/WARFARIN/SODIUM/

	∂ PHARM BASICS	2MG	N88719 001 JUN 27, 1985
	∂	2.5MG	N88720 001 AUG 06, 1985
	∂	5MG	N88721 001 JUL 02, 1985

ACETAMINOPHEN

SUPPOSITORY; RECTAL
ACEPHEN
G AND W 120MG¤ N72218 001
MAR 27, 1992
325MG¤ N72344 001
MAR 27, 1992
650MG¤ N72237 001
MAR 27, 1992

CHLORHEXIDINE GLUCONATE

SOLUTION; TOPICAL
MICROCOL
JOHNSON AND JOHNSON 0.5%¤ N72292 001
JAN 28, 1992

DIPHENHYDRAMINE HYDROCHLORIDE

SYRUP; ORAL
SILPHEN
SILARX 12.5MG/5ML¤ N72646 001
FEB 27, 1992

IBUPROFEN

TABLET; ORAL
IBUPROFEN
>ADD> TAG 200MG¤ N73141 001
>ADD> MAY 29, 1992

INSULIN BIOSYNTHETIC HUMAN; INSULIN SUSP ISOPHANE BIOSYNTHETIC HUMAN

INJECTABLE; INJECTION
HUMULIN 50/50
LILLY 50 UNITS/ML;50 UNITS/ML¤ N20100 001
APR 29, 1992

LOPERAMIDE HYDROCHLORIDE

SOLUTION; ORAL
LOPERAMIDE HCL
PERRIGO 1MG/5ML¤ N73243 001
JAN 21, 1992
ROXANE 1MG/5ML¤ N73079 001
APR 30, 1992

SODIUM MONOFLUOROPHOSPHATE

PASTE; DENTAL
EXTRA-STRENGTH AIM
/A/CHESEBROUGH/PONDS/ /1.2%/ /N19518/001/
/JUN/03,/1987/
CHESEBROUGH PONDS 1.2% N19518 001
JUN 03, 1987

LOPERAMIDE HYDROCHLORIDE

SOLUTION; ORAL
LOPERAMIDE HCL

PERRIGO	1MG/5ML*	N73243 001 JAN 21, 1992
ROXANE	1MG/5ML*	N73079 001 APR 30, 1992

DEXTRAN, 75, 6% INVERTED SUGAR 10% IN SODIUM CHLORIDE 0.9%
INJECTABLE; INJECTION
6% GENTRAN 75 AND 10% TRAVERT

TRAVENOL LABS	6GM/100ML;0.9GM/100ML 0.9GM/100ML	N08788

UROKINASE

INJECTABLE; INJECTION
BREOKINASE

STERLING DRUG	250,000 IU/VIAL	N17873

ORPHAN DRUG PRODUCT DESIGNATIONS

SECTION 526 OF THE FEDERAL FOOD, DRUG, AND COSMETIC ACT CONTAINS PROVISIONS WHEREBY FDA MAY DESIGNATE A SPONSOR'S DRUG, ANTIBIOTIC, OR BIOLOGICAL PRODUCT AS A "DESIGNATED ORPHAN DRUG." SECTION 527 OF THE ACT ESTABLISHES A PROCESS WHEREBY A SPONSOR MAY RECEIVE SEVEN YEARS OF EXCLUSIVE APPROVAL STATUS IF THAT SPONSOR IS THE FIRST TO ACHIEVE NEW DRUG, ANTIBIOTIC, OR BIOLOGICAL PRODUCT APPROVAL FOR A DESIGNATED ORPHAN DRUG FOR THE DESIGNATED INDICATION(S). THE EXCLUSIVE APPROVAL MAY BE REVOKED BY WRITTEN CONSENT OF THE SPONSOR OR BY FDA ACTION AFTER FINDING THAT THE SPONSOR HOLDING EXCLUSIVE APPROVAL CANNOT ASSURE THE AVAILABILITY OF SUFFICIENT QUANTITIES OF THE DRUG TO MEET THE NEEDS OF PATIENTS WITH THE DESIGNATED ORPHAN INDICATION(S).

WHEN A PRODUCT IS GRANTED ORPHAN DRUG DESIGNATION, IT WILL APPEAR IN THIS SECTION. ONCE A BIOLOGICAL OR DRUG PRODUCT IS LICENSED/APPROVED FOR MARKETING, IT WILL BE LISTED IN THIS SECTION AND ASTERISKED, AS APPROPRIATE, TO DENOTE MARKETING/EXCLUSIVE APPROVAL STATUS. IN ADDITION, THE EXCLUSIVITY EXPIRATION DATE WILL BE DISPLAYED FOLLOWING THE APPROVED DESIGNATED INDICATION(S).

THE FOLLOWING DRUGS AND BIOLOGICALS HAVE BEEN GRANTED ORPHAN DRUG DESIGNATION PURSUANT TO SECTION 526 OF THE FOOD, DRUG, AND COSMETIC ACT AS AMENDED BY THE ORPHAN DRUG ACT [PUBLIC LAW 97-414].

ORPHAN DRUG PRODUCT DESIGNATIONS

BIOLOGICAL DESIGNATIONS

NAME OF BIOLOGICAL	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: ALDESLEUKIN TRADE: PROLEUKIN*/**	TREATMENT OF PRIMARY IMMUNODEFICIENCY DISEASE ASSOCIATED WITH T-CELL DEFECTS.*/** [MAY 5, 1999]	CETUS CORPORATION
GENERIC: ANANAIN, COMOSAIN TRADE: VIANAIN	FOR THE ENZYMATIC DEBRIDEMENT OF SEVERE BURNS.	GENZYME CORPORATION
GENERIC: ANTITHROMBIN III TRADE: THROMBATE III*/**	USE AS REPLACEMENT THERAPY IN CONGENITAL DEFICIENCY OF ANTITHROMBIN-III FOR PREVENTION AND TREATMENT OF OF THROMBOSIS AND PULMONARY EMBOLI. [DEC 13, 1996]	CUTTER BIOLOGICAL
GENERIC: BOTULINUM TOXIN TYPE B TRADE: NOT ESTABLISHED	TREATMENT OF CERVICAL DYSTONIA.	ATHENA NEUROSCIENCES, INC
GENERIC: CILIARY NEUROTROPHIC FACTOR TRADE: NOT ESTABLISHED	TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS.	ROGENERON PHARMACEUTICALS, INC
GENERIC: CILIARY NEUROTROPHIC FACTOR, RECOMBINANT HUMAN TRADE: NOT ESTABLISHED	TREATMENT OF SPINAL MUSCULAR ATROPHIES. TREATMENT OF MOTOR NEURON DISEASE (INCLUDING AMYOTROPHIC LATERAL SCLEROSIS, PROGRESSIVE MUSCULAR ATROPHY, PROGRESSIVE BULBAR PALSY, AND PRIMARY LATERAL SCLEROSIS).	SYNTEX-SYNERGEN NEUROSCIENCE

GENERIC: CILIARY NEUROTROPHIC FACTOR, RECOMBINANT HUMAN TRADE: NOT ESTABLISHED	TREATMENT OF SPINAL MUSCULAR ATROPHIES. TREATMENT OF MOTOR NEURON DISEASE (INCLUDING AMYOTROPHIC LATERAL SCLEROSIS, PROGRESSIVE MUSCULAR ATROPHY, PROGRESSIVE BULBAR PALSY, AND PRIMARY LATERAL SCLEROSIS).	*SYNTEX-SYNERGEN NEUROSCIENCE*

ORPHAN DRUG PRODUCT DESIGNATIONS

BIOLOGICAL DESIGNATIONS

NAME OF BIOLOGICAL	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR TRADE: NOT ESTABLISHED	FOR CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN REPLACEMENT THERAPY IN CYSTIC FIBROSIS PATIENTS.	GENZYME CORPORATION
GENERIC: HIV NEUTRALIZING ANTIBODIES TRADE: IMMUPATH	TREATMENT OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS).	HEMACARE CORPORATION
GENERIC: HUMAN IMMUNODEFICIENCY VIRUS IMMUNE GLOBULIN TRADE: NOT ESTABLISHED	TREATMENT OF HIV-INFECTED PREGNANT WOMEN AND INFANTS OF HIV-INFECTED MOTHERS.	ABBOTT LABORATORIES
GENERIC: IMPORTED FIRE ANT VENOM, ALLERGENIC EXTRACT TRADE: NOT ESTABLISHED	FOR SKIN TESTING OF VICTIMS OF FIRE ANT STINGS TO CONFIRM FIRE ANT SENSITIVITY AND IF POSITIVE, FOR USE AS IMMUNOTHERAPY FOR THE PREVENTION OF IgE-MEDIATED ANAPHYLACTIC REACTIONS.	ALK LABORATORIES, INC
GENERIC: SARGRAMOSTIM TRADE: LEUKINE*/**	TREATMENT OF NEUTROPENIA ASSOCIATED WITH BONE MARROW TRANSPLANT, FOR THE PROMOTION OF EARLY ENGRAFTMENT, AND FOR THE TREATMENT OF GRAFT FAILURE AND DELAY OF ENGRAFTMENT.*/** [DEC 31, 1998] TREATMENT OF NEUTROPENIA ASSOCIATED WITH BONE MARROW TRANSPLANTS IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA, HODGKIN'S DISEASE AND ACUTE LYMPHOBLASTIC LEUKEMIA.*/** [MAR 05, 1998]	IMMUNEX
GENERIC: TECHNETIUM TC99M MURINE MONOCLONAL ANTIBODY (IGG2A) TO BCE TRADE: IMMURAID-LL-2[99mTc]	DIAGNOSTIC IMAGING IN THE EVALUATION OF THE EXTENT OF DISEASE IN PATIENTS WITH HISTOLOGICALLY CONFIRMED DIAGNOSIS OF NON-HODGKIN'S B-CELL LYMPHOMA, ACUTE B-CELL LYMPHOBLASTIC LEUKEMIA (IN CHILDREN AND ADULTS), AND CHRONIC B-CELL LYMPHOCYTIC LEUKEMIA.	IMMUNOMEDICS, INC

ORPHAN DRUG PRODUCT DESIGNATIONS

DRUG DESIGNATIONS

NAME OF DRUG	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: ANARITIDE ACETATE TRADE: AURICULIN	IMPROVEMENT OF EARLY RENAL ALLOGRAFT FUNCTION FOLLOWING RENAL TRANSPLANTATION.	SCIOS, INC
GENERIC: ARGININE BUTYRATE TRADE: NOT ESTABLISHED	TREATMENT OF BETA-HEMOGLOBINOPATHIES AND BETA-THALASSEMIA.	SUSAN P. PERRINE, M.D.
GENERIC: BACLOFEN (INTRATHECAL) TRADE: LIORESAL	TREATMENT OF INTRACTABLE SPASTICITY CAUSED BY SPINAL CORD INJURY, MULTIPLE SCLEROSIS, AND OTHER SPINAL DISEASES (INCLUDING SPINAL ISCHEMIA, SPINAL TUMOR, TRANSVERSE MYELITIS, CERVICAL SPONDYLOSIS, AND DEGENERATIVE MYELOPATHY.	MEDTRONIC, INC
GENERIC: BUTYRYLCHOLINESTERASE TRADE: NOT ESTABLISHED	FOR THE REDUCTION AND CLEARANCE OF TOXIC BLOOD LEVELS OF COCAINE ENCOUNTERED DURING A DRUG OVERDOSE.	PHARMAVENE, INC
GENERIC: DAPSONE TRADE: DAPSONE	FOR THE COMBINATION TREATMENT OF PNEUMOCYSTIS CARINII PNEUMONIA IN CONJUNCTION WITH TRIMETHOPRIM.	JACOBUS PHARMACEUTICAL COMPANY
GENERIC: DIAZEPAM VISCOUS SOLUTION FOR RECTAL ADMINISTRATION TRADE: DIASTAT	TREATMENT OF ACUTE REPETITIVE SEIZURES.	UPSHER SMITH LABORATORIES, INC
GENERIC: HUMAN THYROID STIMULATING HORMONE (TSH) TRADE: THYROGEN	AS AN ADJUNCT IN THE DIAGNOSIS OF THYROID CANCER.	GENZYME CORPORATION
GENERIC: L-BACLOFEN TRADE: NEURALGON	TREATMENT OF INTRACTABLE SPASTICITY IN CHILDREN WITH CEREBRAL PALSY.	WTD, INC
GENERIC: LIOTHYRONINE SODIUM TRADE: TRIOSTAT*/**	TREATMENT OF MYXEDEMA COMA/PRE-COMA. [DEC 31, 1998]	SMITHKLINE BEECHAM
GENERIC: LOXORIBINE TRADE: NOT ESTABLISHED	TREATMENT OF COMMON VARIABLE IMMUNODEFICIENCY.	R.W. JOHNSON RESEARCH INSTITUTE
GENERIC: MELPHALAN TRADE: ALKERAN FOR INJECTION	TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA FOR WHOM ORAL THERAPY IS INAPPROPRIATE. FOR USE IN HYPERTHERMIC REGIONAL LIMB PERFUSION TO TREAT METASTATIC MELANOMA OF THE EXTREMITY.	BURROUGHS WELLCOME COMPANY

GENERIC: MELPHALAN TRADE: ALKERAN FOR INJECTION	TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA FOR WHOM ORAL THERAPY IS INAPPROPRIATE. FOR USE IN HYPERTHERMIC REGIONAL LIMB PERFUSION TO TREAT METASTATIC MELANOMA OF THE EXTREMITY.	BURROUGHS WELLCOME COMPANY

ORPHAN DRUG PRODUCT DESIGNATIONS

DRUG DESIGNATIONS

NAME OF DRUG	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: PAPAVERINE (TOPICAL GEL) TRADE: NOT ESTABLISHED	TREATMENT OF SEXUAL DYSFUNCTION IN SPINAL CORD INJURY PATIENTS.	PHARMEDIC COMPANY
GENERIC: PARA-AMINOSALICYLIC ACID TRADE: NOT ESTABLISHED	TREATMENT OF TUBERCULOSIS INFECTIONS.	JACOBUS PHARMACEUTICAL COMPANY
GENERIC: PILOCARPINE HCL TRADE: NOT ESTABLISHED	TREATMENT OF XEROSTOMIA AND KERATOCONJUNCTIVITIS SICCA IN SJOGREN'S SYNDROME PATIENTS.	MGI PHARMA, INC
GENERIC: POLYMERIC OXYGEN TRADE: NOT ESTABLISHED	TREATMENT OF SICKLE CELL ANEMIA.	CAPMED, USA
GENERIC: PPI-002 TRADE: NOT ESTABLISHED	TREATMENT OF MALIGNANT MESOTHELIOMA.	PLEXUS PHARMACEUTICALS, INC
GENERIC: SODIUM MONOMERCAPTOUNDECAHYDRO-CLOSODODECABORATE TRADE: BOROCELL	FOR USE IN BORON NEUTRON CAPTURE THERAPY IN THE TREATMENT OF GLIOBLASTOMA MULTIFORME.	NEUTRON TECHNOLOGY CORPORATION
GENERIC: 9-CIS RETINOIC ACID TRADE: NOT ESTABLISHED	TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA.	LIGAND PHARMACUETICALS, INC

DRUG PRODUCTS WHICH MUST DEMONSTRATE IN VIVO BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO MAY 1992 ADDITIONS

BIOPHARMACEUTIC GUIDANCE AVAILABILITY

THE FOLLOWING IS A LIST OF GUIDANCES AVAILABLE FOR IN VIVO BIOEQUIVALENCE STUDIES AND IN VITRO DISSOLUTION TESTING AVAILABLE FROM THE DIVISION OF BIOEQUIVALENCE, HFD-650, MPN-2 ROOM 278, 5600 FISHERS LANE, ROCKVILLE, MD 20857. COMMENTS AND SUGGESTIONS CONCERNING THESE GUIDANCES ARE ENCOURAGED AND SHOULD BE SENT TO THE DIVISION OF BIOEQUIVALENCE.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 12TH EDITION FOR A FULL LISTING OF BIOPHARMACEUTIC GUIDANCE AVAILABILITY DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

DRUG NAME (DOSAGE FORM)	DATE	REVISED DATE
DIFLUNISAL (TABLET)	MAY 16, 1992	
DILTIAZEM HYDROCHLORIDE (TABLET)	MAY 16, 1992	
NADOLOL (TABLET)	MAY 16, 1992	

ANDA SUITABILITY PETITIONS

THE FOLLOWING ARE TWO LISTS OF PETITIONS FILED UNDER SECTION 505(j)(2)(C) OF THE ACT WHERE THE AGENCY HAS DETERMINED THAT THE REFERENCED PRODUCT: (1) IS SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS APPROVED) OR (2) IS NOT SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS DENIED). THE DETERMINATION THAT AN ANDA WILL BE APPROVED IS NOT MADE UNTIL THE ANDA ITSELF IS SUBMITTED AND REVIEWED BY THE AGENCY. A COPY OF EACH PETITION IS LISTED BY DOCKET NUMBER ON PUBLIC DISPLAY IN FDA'S DOCKETS MANAGEMENT BRANCH, HFA-305, ROOM 4-62, 5600 FISHERS LANE, ROCKVILLE, MD 20857.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 12TH EDITION FOR A FULL LISTING OF ANDA SUITABILITY PETITIONS DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

PETITIONS APPROVED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	PETITION	REASON FOR STATUS
ALBUTEROL SULFATE CAPSULE, EXTENDED RELEASE; ORAL	EQ 4MG BASE	91 P-0348/ CP1	HAMER	NEW DOSAGE FORM	APPROVED MAR 17, 1992
NITROGLYCERIN IN DEXTROSE 5% INJECTABLE; INJECTION	5MG/ML (50ML/CONTAINER)	91 P-0387/ CP1	ABBOTT	NEW STRENGTH	APPROVED FEB 18, 1992
NITROGLYCERIN IN DEXTROSE 5% INJECTABLE; INJECTION	10MG/ML (100ML/CONTAINER)	91 P-0387/ CP1	ABBOTT	NEW STRENGTH	APPROVED FEB 18, 1992

ANDA SUITABILITY PETITIONS

PETITIONS DENIED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	PETITION	REASON FOR STATUS
ETOPOSIDE INJECTABLE; INJECTION	20MG/ML (50ML/VIAL)	91 P-0076/ CP1	ADRIA	NEW STRENGTH	DENIED FEB 19, 1992

EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE EXCLUSIVITY COLUMN, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 12TH EDITION FOR A FULL LISTING OF EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). ONLY NEW CODES WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

REFERENCES
NEW INDICATION

I-67	TREATMENT OF ACUTE ASTHMATIC ATTACKS IN CHILDREN SIX YEARS OF AGE AND OLDER
I-68	CENTRAL PRECOCIOUS PUBERTY
I-69	SHORT TERM TREATMENT OF PATIENTS WITH SYMPTOMS OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), AND FOR THE SHORT TERM TREATMENT OF ESOPHAGITIS DUE TO GERD INCLUDING ULCERATIVE DISEASE DIAGNOSED BY ENDOSCOPY
I-70	USE IN COMBINATION WITH 5-FLUOROURACIL TO PROLONG SURVIVAL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER
I-71	VARICELLA INFECTIONS (CHICKENPOX)
I-72	PREVENTION OF CMV DISEASE IN TRANSPLANT PATIENTS AT RISK FOR CMV DISEASE
I-73	INITIATE AND MAINTAIN MONITORED ANESTHESIA CARE (MAC) SEDATION DURING DIAGNOSTIC PROCEDURES
I-74	INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY

REFERENCES
PATENT USE CODE

U-57	OPHTHALMIC USE OF NORFLOXACIN
U-58	METHOD OF TREATING INFLAMMATORY INTESTINAL DISEASES
U-59	METHOD OF TREATING HYPERCHOLESTEROLEMIA
U-60	NASAL ADMINISTRATION OF BUTORPHANOL

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	18828 001	ACYCLOVIR; ZOVIRAX				I-71	FEB 26, 1995
	19909 001	ACYCLOVIR; ZOVIRAX				I-71	FEB 26, 1995
	20089 001	ACYCLOVIR; ZOVIRAX				I-71	FEB 26, 1995
	20089 002	ACYCLOVIR; ZOVIRAX				I-71	FEB 26, 1995
>ADD>	19851 001	BENAZEPRIL HYDROCHLORIDE; LOTENSIN	4410520	OCT 18, 2002		NCE	JUN 25, 1996
>DLT>	~~19851 001~~	~~BENAZEPRIL HYDROCHLORIDE; LOTENSIN~~	~~4410520~~	~~OCT 18, 2000~~		~~NCE~~	~~JUN 25, 1996~~
>ADD>	19851 002	BENAZEPRIL HYDROCHLORIDE; LOTENSIN	4410520	OCT 18, 2002		NCE	JUN 25, 1996
>DLT>	~~19851 002~~	~~BENAZEPRIL HYDROCHLORIDE; LOTENSIN~~	~~4410520~~	~~OCT 18, 2000~~		~~NCE~~	~~JUN 25, 1996~~
>ADD>	19851 003	BENAZEPRIL HYDROCHLORIDE; LOTENSIN	4410520	OCT 18, 2002		NCE	JUN 25, 1996
>DLT>	~~19851 003~~	~~BENAZEPRIL HYDROCHLORIDE; LOTENSIN~~	~~4410520~~	~~OCT 18, 2000~~		~~NCE~~	~~JUN 25, 1996~~
>ADD>	19851 004	BENAZEPRIL HYDROCHLORIDE; LOTENSIN	4410520	OCT 18, 2002		NCE	JUN 25, 1996
>DLT>	~~19851 004~~	~~BENAZEPRIL HYDROCHLORIDE; LOTENSIN~~	~~4410520~~	~~OCT 18, 2000~~		~~NCE~~	~~JUN 25, 1996~~
>ADD>	20033 001	BENAZEPRIL HYDROCHLORIDE; LOTENSIN HCT	4410520	OCT 18, 2002		NCE	JUN 25, 1996
>ADD>						NC	MAY 19, 1995
>ADD>	20033 002	BENAZEPRIL HYDROCHLORIDE; LOTENSIN HCT	4410520	OCT 18, 2002		NCE	JUN 25, 1996
>ADD>						NC	MAY 19, 1995
>ADD>	20033 003	BENAZEPRIL HYDROCHLORIDE; LOTENSIN HCT	4410520	OCT 18, 2002		NCE	JUN 25, 1996
>ADD>						NC	MAY 19, 1995
>ADD>	20033 004	BENAZEPRIL HYDROCHLORIDE; LOTENSIN HCT	4410520	OCT 18, 2002		NCE	JUN 25, 1996
>ADD>						NC	MAY 19, 1995
	19001 001	BEPRIDIL HYDROCHLORIDE; BEPADIN	RE30577	JUN 08, 1995		NCE	DEC 28, 1995
	19001 002	BEPRIDIL HYDROCHLORIDE; BEPADIN	RE30577	JUN 08, 1995		NCE	DEC 28, 1995
	19001 003	BEPRIDIL HYDROCHLORIDE; BEPADIN	RE30577	JUN 08, 1995		NCE	DEC 28, 1995
	19548 001	BITOLTEROL MESYLATE; TORNALATE	4336400	JUN 22, 1999	U-5		
			4138581	FEB 06, 1998		NDF	FEB 19, 1995
	19890 001	BUTORPHANOL TARTRATE; STADOL	4464378	AUG 07, 2001	U-60	NDF	DEC 12, 1994
	19847 001	CIPROFLOXACIN; CIPRO	4808583	FEB 28, 2006			
			4705789	NOV 10, 2004			
>ADD>			4670444	OCT 01, 2002		NCE	OCT 22, 1992
>DLT>			~~4670444~~	~~JUN 02, 2004~~		~~NCE~~	~~OCT 22, 1992~~
	19857 001	CIPROFLOXACIN; CIPRO IN DEXTROSE 5%	4957922	SEP 18, 2007			
			4808583	FEB 28, 2006			
			4705789	NOV 10, 2004			
>ADD>			4670444	OCT 01, 2002		NCE	OCT 22, 1992
>DLT>			~~4670444~~	~~JUN 02, 2004~~		~~NCE~~	~~OCT 22, 1992~~

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	19858 001	CIPROFLOXACIN; CIPRO IN SODIUM CHLORIDE 0.9%	4957922	SEP 18, 2007			
			4808583	FEB 28, 2006			
			4705789	NOV 10, 2004			
			4670444	OCT 01, 2002		NCE	OCT 22, 1992
>ADD>			4670444	JUN 02, 2004		NCE	OCT 22, 1992
>DLT>							
>ADD>	19537 002	CIPROFLOXACIN HYDROCHLORIDE; CIPRO	4670444	OCT 01, 2002	U-36	NCE	OCT 22, 1992
>DLT>	19537 002	CIPROFLOXACIN HYDROCHLORIDE; CIPRO	4670444	JUN 02, 2004	U-36	NCE	OCT 22, 1992
>ADD>	19537 003	CIPROFLOXACIN HYDROCHLORIDE; CIPRO	4670444	OCT 01, 2002	U-36	NCE	OCT 22, 1992
>DLT>	19537 003	CIPROFLOXACIN HYDROCHLORIDE; CIPRO	4670444	JUN 02, 2004	U-36	NCE	OCT 22, 1992
>ADD>	19537 004	CIPROFLOXACIN HYDROCHLORIDE; CIPRO	4670444	OCT 01, 2002	U-36	NCE	OCT 22, 1992
>DLT>	19537 004	CIPROFLOXACIN HYDROCHLORIDE; CIPRO	4670444	JUN 02, 2004	U-36	NCE	OCT 22, 1992
>ADD>	19992 001	CIPROFLOXACIN HYDROCHLORIDE; CILOXAN	4670444	OCT 01, 2002		NDF	DEC 31, 1993
>DLT>	19992 001	CIPROFLOXACIN HYDROCHLORIDE; CILOXAN	4670444	JUN 02, 2004		NDF	DEC 31, 1993
	20037 001	DICLOFENAC SODIUM; VOLTAREN	4960799	OCT 02, 2007		NDF	MAR 28, 1994
>ADD>	20027 001	DILTIAZEM HYDROCHLORIDE; CARDIZEM				NCE	NOV 05, 1992
>ADD>	20027 002	DILTIAZEM HYDROCHLORIDE; CARDIZEM				NCE	NOV 05, 1992
>ADD>	20062 002	DILTIAZEM HYDROCHLORIDE; CARDIZEM CD	5002776	MAR 26, 2008		NCE	NOV 05, 1992
			4894240	JAN 16, 2007		NP	DEC 27, 1994
>ADD>	20062 003	DILTIAZEM HYDROCHLORIDE; CARDIZEM CD	5002776	MAR 26, 2008		NCE	NOV 05, 1992
			4894240	JAN 16, 2007		NP	DEC 27, 1994
>ADD>	20062 004	DILTIAZEM HYDROCHLORIDE; CARDIZEM CD				NP	DEC 27, 1994
						NCE	NOV 05, 1992
>ADD>	20092 001	DILTIAZEM HYDROCHLORIDE; DILACOR XR				NP	DEC 27, 1994
>ADD>						NCE	NOV 05, 1992
>ADD>	20092 002	DILTIAZEM HYDROCHLORIDE; DILACOR XR				NP	DEC 27, 1994
>ADD>						NCE	NOV 05, 1992
>ADD>	20092 003	DILTIAZEM HYDROCHLORIDE; DILACOR XR				NCE	MAR 07, 1996
>ADD>			4701460	MAR 06, 2005		NCE	MAR 07, 1996
>ADD>	19946 001	DOXACURIUM CHLORIDE; NUROMAX	4701460	OCT 20, 2004		I-69	DEC 10, 1994
>DLT>	19946 001	DOXACURIUM CHLORIDE; NUROMAX	4283408	AUG 11, 2000		I-69	DEC 10, 1994
	19462 001	FAMOTIDINE; PEPCID	4283408	AUG 11, 2000		I-69	DEC 10, 1994
	19462 002	FAMOTIDINE; PEPCID	4283408	AUG 11, 2000		NCE	JUL 25, 1996
	19527 001	FAMOTIDINE; PEPCID	4264611	APR 28, 1998		NCE	JUL 25, 1996
	19834 001	FELODIPINE; PLENDIL	4264611	APR 28, 1998		NCE	APR 18, 1996
	19834 002	FELODIPINE; PLENDIL	4357324	NOV 02, 2001		NCE	APR 18, 1996
>ADD>	20038 001	FLUDARABINE PHOSPHATE; FLUDARA	4357324	NOV 02, 1999			
>DLT>	20038 001	FLUDARABINE PHOSPHATE; FLUDARA					

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20068 001	FOSCARNET SODIUM; FOSCAVIR	4771041	JUL 29, 1997			
			4665062	JUL 29, 1997			
			4339445	JUL 29, 1997			
			4215113	JUL 29, 1997		NCE	SEP 27, 1996
			4337201	JUN 29, 2001		NCE	MAY 16, 1996
>ADD>	19915 002	FOSINOPRIL SODIUM; MONOPRIL	~~4337201~~	~~JUN 29, 1999~~		~~NCE~~	~~MAY 16, 1996~~
>DLT>	~~19915 002~~	~~FOSINOPRIL SODIUM; MONOPRIL~~	4337201	JUN 29, 2001		NCE	MAY 16, 1996
>ADD>	19915 003	FOSINOPRIL SODIUM; MONOPRIL	~~4337201~~	~~JUN 29, 1999~~		~~NCE~~	~~MAY 16, 1996~~
>DLT>	~~19915 003~~	~~FOSINOPRIL SODIUM; MONOPRIL~~	4507305	OCT 19, 1999	U-35	I-72	MAY 15, 1995
>ADD>	19661 001	GANCICLOVIR SODIUM; CYTOVENE	4916163	APR 10, 2007			
	20051 001	GLYBURIDE; GLYNASE	4735805	APR 05, 2005		NCE	MAY 01, 1994
			3507961	APR 21, 1992		NP	MAR 04, 1995
>ADD>			3507954	APR 21, 1992			
			3454635	APR 21, 1992			
			3426067	APR 21, 1992			
			4916163	APR 10, 2007			
	20051 002	GLYBURIDE; GLYNASE	4735805	APR 05, 2005		NCE	MAY 01, 1994
>ADD>			3507961	APR 21, 1992		NP	MAR 04, 1995
			3507954	APR 21, 1992			
			3454635	APR 21, 1992			
			3426067	APR 21, 1992			
						NP	MAR 04, 1995
	20055 001	GLYBURIDE; GLUBATE				NCE	MAY 01, 1994
						NP	MAR 04, 1995
>ADD>	20055 002	GLYBURIDE; GLUBATE				NCE	MAY 01, 1994
						D-1	DEC 31, 1994
>ADD>						D-1	DEC 31, 1994
	19967 001	HALOBETASOL PROPIONATE; ULTRAVATE				NCE	AUG 01, 1994
	19968 001	HALOBETASOL PROPIONATE; ULTRAVATE	4012444	MAR 15, 1994		NCE	AUG 01, 1994
	19046 001	HYDROCHLOROTHIAZIDE; NORMOZIDE	4012444	MAR 15, 1994		NCE	AUG 01, 1994
	19046 002	HYDROCHLOROTHIAZIDE; NORMOZIDE	4012444	MAR 15, 1994		NCE	AUG 01, 1994
	19046 003	HYDROCHLOROTHIAZIDE; NORMOZIDE	4012444	MAR 15, 1994		NCE	AUG 01, 1994
	19046 004	HYDROCHLOROTHIAZIDE; NORMOZIDE	4012444	MAR 15, 1994		NCE	AUG 01, 1994
	19174 001	HYDROCHLOROTHIAZIDE; TRANDATE HCT	4012444	MAR 15, 1994		NCE	AUG 01, 1994
	19174 002	HYDROCHLOROTHIAZIDE; TRANDATE HCT	4012444	MAR 15, 1994		NCE	AUG 01, 1994
	19174 003	HYDROCHLOROTHIAZIDE; TRANDATE HCT	4012444	MAR 15, 1994		NCE	AUG 01, 1994
	19174 004	HYDROCHLOROTHIAZIDE; TRANDATE HCT				NC	JAN 30, 1995
	19261 001	HYDROXYAMPHETAMINE HYDROBROMIDE; PAREMYD				NP	APR 29, 1995
	20100 001	INSULIN BIOSYNTHETIC HUMAN; HUMULIN 50/50					

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
						NS	JAN 22, 1995
						NS	JAN 22, 1995
>ADD>	19710 004	IOVERSOL; OPTIRAY 300				I-74	JAN 22, 1995
>ADD>	19710 005	IOVERSOL; OPTIRAY 350	4089969	MAY 16, 1997	U-55	NDF	DEC 20, 1994
>ADD>						NCE	NOV 30, 1994
	19645 001	KETOROLAC TROMETHAMINE; TORADOL					
						I-70	DEC 12, 1994
	08107 001	LEUCOVORIN CALCIUM; LEUCOVORIN CALCIUM				I-70	DEC 12, 1994
	08107 002	LEUCOVORIN CALCIUM; LEUCOVORIN CALCIUM				I-70	DEC 12, 1994
	08107 004	LEUCOVORIN CALCIUM; LEUCOVORIN CALCIUM				I-70	DEC 12, 1994
	08107 005	LEUCOVORIN CALCIUM; LEUCOVORIN CALCIUM					
	19732 001	LEUPROLIDE ACETATE; LUPRON DEPOT	4917893	MAR 24, 2004			
			4849228	JUL 18, 2006			
			4728721	MAR 01, 2005			
			4677191	JUN 30, 2004			
			4652441	MAR 24, 2004			
	20011 001	LEUPROLIDE ACETATE; LUPRON DEPOT	4917893	MAR 24, 2004			
			4849228	JUL 18, 2006			
			4728721	MAR 01, 2005			
			4677191	JUN 30, 2004			
			4652441	MAR 24, 2004			
						ODE	DEC 31, 1998
	20105 001	LIOTHYRONINE SODIUM; TRIOSTAT	4528287	JUL 09, 2002	U-36	NCE	FEB 21, 1997
	20013 001	LOMEFLOXACIN HYDROCHLORIDE; MAXAQUIN				NCE	DEC 24, 1992
	19651 001	MESALAMINE; ASACOL				NDF	JAN 31, 1995
						I-67	NOV 14, 1994
	17659 001	METAPROTERENOL SULFATE; ALUPENT	3998790	APR 08, 1992		NE	JAN 10, 1995
	19962 001	METOPROLOL SUCCINATE; TOPROL XL	3876802	APR 08, 1992			
			3998790	APR 08, 1992		NE	JAN 10, 1995
	19962 002	METOPROLOL SUCCINATE; TOPROL XL	3876802	APR 08, 1992			
			3998790	APR 08, 1992		NE	JAN 10, 1995
	19962 003	METOPROLOL SUCCINATE; TOPROL XL	3876802	APR 08, 1992			
			4761418	AUG 02, 2005		NCE	JAN 22, 1997
	20098 001	MIVACURIUM CHLORIDE; MIVACRON	4761418	AUG 02, 2005		NCE	JAN 22, 1997
	20098 002	MIVACURIUM CHLORIDE; MIVACRON IN DEXTROSE 5%	4420639	DEC 13, 2000		NCE	DEC 24, 1996
	19583 001	NABUMETONE; RELAFEN	4061779	DEC 06, 1994	U-19		
			4420639	DEC 13, 2000		NCE	DEC 24, 1996
	19583 002	NABUMETONE; RELAFEN	4061779	DEC 06, 1994	U-19		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
					I-68	FEB 26, 1995
19886 001	NAFARELIN ACETATE; SYNAREL	4234571	NOV 18, 1997		NCE	FEB 13, 1995
20109 001	NAFARELIN ACETATE; SYNAREL				I-68	FEB 26, 1995
					NDF	JAN 30, 1995
19734 001	NICARDIPINE HYDROCHLORIDE; CARDENE				NCE	DEC 21, 1993
					NDF	FEB 21, 1995
20005 001	NICARDIPINE HYDROCHLORIDE; CARDENE SR				NDF	FEB 21, 1995
20005 002	NICARDIPINE HYDROCHLORIDE; CARDENE SR				NDF	FEB 21, 1995
20005 003	NICARDIPINE HYDROCHLORIDE; CARDENE SR	4946853	AUG 07, 2007	U-56	NS	JAN 28, 1995
19983 001	NICOTINE; PROSTEP	4946853	AUG 07, 2007	U-56	NS	JAN 28, 1995
19983 002	NICOTINE; PROSTEP	5016652	MAY 21, 2008		NDF	NOV 07, 1994
20076 001	NICOTINE; HABITROL	5016652	MAY 21, 2008		NDF	NOV 07, 1994
20076 002	NICOTINE; HABITROL	5016652	MAY 21, 2008		NDF	NOV 07, 1994
20076 003	NICOTINE; HABITROL				NP	APR 22, 1995
20150 001	NICOTINE; NICOTROL				NP	APR 22, 1995
20150 002	NICOTINE; NICOTROL				NP	APR 22, 1995
20150 003	NICOTINE; NICOTROL					
20165 001	NICOTINE; NICODERM	5004610	APR 02, 2008			
		4144317	SEP 09, 1992		NDF	NOV 07, 1994
20165 002	NICOTINE; NICODERM	5004610	APR 02, 2008			
		4144317	SEP 09, 1992		NDF	NOV 07, 1994
20165 003	NICOTINE; NICODERM	5004610	APR 02, 2008			
		4144317	SEP 09, 1992		NDF	NOV 07, 1994
19757 001	NORFLOXACIN; CHIBROXIN	4551456	NOV 05, 2002	U-57		
20087 001	OFLOXACIN; FLOXIN IN DEXTROSE 5%	4382892	MAY 10, 2000		NCE	DEC 28, 1995
20087 002	OFLOXACIN; FLOXIN	4382892	MAY 10, 2000		NCE	DEC 28, 1995
20087 003	OFLOXACIN; FLOXIN	4382892	MAY 10, 2000		NCE	DEC 28, 1995
20087 004	OFLOXACIN; FLOXIN IN DEXTROSE 5%	4382892	MAY 10, 2000		NCE	DEC 28, 1995
20087 005	OFLOXACIN; FLOXIN IN DEXTROSE 5%	4382892	MAY 10, 2000		NCE	DEC 28, 1995
19715 001	OLSALAZINE SODIUM; DIPENTUM	4559330	AUG 04, 2004	U-58	NCE	JUL 31, 1995
19775 001	PRAZOSIN HYDROCHLORIDE; MINIPRESS XL				NDF	JAN 29, 1995
19775 002	PRAZOSIN HYDROCHLORIDE; MINIPRESS XL				NDF	JAN 29, 1995
19157 001	PREDNISOLONE SODIUM PHOSPHATE; PEDIAPRED					
>ADD> 19627 001	PROPOFOL; DIPRIVAN	4448774	MAY 15, 2001			
19766 001	SIMVASTATIN; ZOCOR	4798846	NOV 01, 1996		I-73	DEC 31, 1994
19766 002	SIMVASTATIN; ZOCOR	4444784	APR 24, 2001	U-59	NCE	DEC 23, 1997
19766 003	SIMVASTATIN; ZOCOR	4444784	APR 24, 2001	U-59	NCE	DEC 23, 1997
19766 004	SIMVASTATIN; ZOCOR	4444784	APR 24, 2001	U-59	NCE	DEC 23, 1997
		4444784	APR 24, 2001	U-59	NCE	DEC 23, 1997

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
20166 001	SODIUM THIOSULFATE; SODIUM THIOSULFATE				NCE	FEB 14, 1997
20043 003	TEMAFLOXACIN HYDROCHLORIDE; OMNIFLOX	4730000	MAR 08, 2005	U-36	NCE	JAN 30, 1997
20043 004	TEMAFLOXACIN HYDROCHLORIDE; OMNIFLOX	4730000	MAR 08, 2005	U-36	NCE	JAN 30, 1997
19614 003	VERAPAMIL HYDROCHLORIDE; VERELAN	4863742	SEP 05, 2006	U-3	NDF	MAY 29, 1993
19655 001	ZIDOVUDINE; RETROVIR	4837208	FEB 09, 2005			
		4833130	FEB 09, 2005		I-47	MAY 02, 1993
		4828838	FEB 09, 2005		ODE	MAR 19, 1994
		4724232	FEB 09, 2005		NCE	MAR 19, 1992
19910 001	ZIDOVUDINE; RETROVIR	4837208	FEB 09, 2005		ODE	MAR 19, 1994
		4833130	FEB 09, 2005		I-47	MAY 02, 1993
		4818538	FEB 09, 2005		NCE	MAR 19, 1992
		4724232	FEB 09, 2005			
19951 001	ZIDOVUDINE; RETROVIR	4837208	FEB 09, 2005		NCE	MAR 19, 1992
		4833130	FEB 09, 2005			
		4818538	FEB 09, 2005		ODE	MAR 19, 1994
		4724232	FEB 09, 2005			

*U.S. Government Printing Office: 1992 — 312-211/40012